电针对大鼠非酒精性脂肪性肝炎的治疗作用及机制研究
|
摘要
目的随着社会的发展及人民生活水平的不断提高，非酒精性脂肪性肝炎(nonalcoholic steatohepatitis，NASH)发病逐渐增多。其病理机制较为复杂，至今尚未完全阐明。其中，游离脂肪酸过多、氧化应激、细胞因子相关性损害等是其重要的病理环节。已有的临床和实验研究表明，脂肪性肝炎与NF-κB、PPAR r的相关性研究文献较少，有必要深入研究，进一步阐明核因子-κB(nuclear factorKappa B NF-κB)、过氧化物酶体增殖物激活受体r(peroxisome prolifera-tor-activated receptor gamma，PPAR r)与NASH之间的关系。NASH尚无理想的治疗药物。中医药在治疗NASH方面具有一定的优势。导师孙国杰教授根据长期临床实践，认为NASH多因长期过食肥甘、体胖少动、七情内伤，致脾失健运，肝失疏泄，痰湿内聚，郁久化热，阴精暗耗，终至形成本虚标实的病理特点。治宜补益肝肾、健脾利湿、化痰逐瘀，穴选肝俞、足三里、丰隆、太冲。我们应用电针刺激患者肝俞、足三里、丰隆、太冲治疗非酒精性脂肪性肝炎，发现电针具有明显的改善非酒精性脂肪性肝炎患者的临床症状、改善肝功能、降低血脂及抗肝纤维化的作用，对非酒精性脂肪性肝炎治疗有较好的临床疗效。本课题采用国内外公认的经典NASH动物模型，结合已有的关于NASH的研究成果，用病理学、生物化学、分子生物学等技术，探讨NASH状态下肝组织NF-κB和PPARrmRNA的表达情况，阐明电针治疗NASH的作用机制，为临床应用电针治疗NASH提供科学依据。
方法将48只SD大鼠称重标记后按随机数字表随机分为2组：正常对照组12只；造模组36只。正常对照组采用普通饲料喂养；造模组采用高脂饲料喂养。实验依据范建高经典造模方法(标准饲料的基础上加2％胆固醇、13％猪油)复制NASH动物模型。12周后，从正常对照组随机抽取2只，造模组随机抽取6只，肝脏病理切片证实造模成功后，取剩余30只造模组大鼠称重，再随机分为模型组10只，电针组10只，药物组10只。正常组不进行电针和药物治疗，同前普通饲料喂养4周；模型对照组，不进行电针和药物治疗，同前高脂饲料喂养4周。针刺组取穴参照新世纪全国高等中医药院校规划教材《实验针灸学》大鼠针灸穴位定位方法及拟人比照法定位，选取双侧肝俞、足三里、丰隆、太冲，自第12周开始每天治疗1次，连续6天后休息1天，共治疗4周；药物组，自第12周开始每天以西药熊去氧胆酸(UDCA)250mg／kg．d的水溶液灌胃，继前高脂饲料喂养4周。各组大鼠在实验第16周隔夜空腹以2％戊巴比妥钠按2ml／kg量麻醉，经下腔静脉采血，迅速按常规分离血清；摘取肝脏。观察动物体重、食欲、行为、状态、毛发及死亡情况，计算肝指数(肝脏湿重／体重×100％)；采用Olympus Au560全自动生化分析仪测定血清ALT、AST、TG、TC、FFA、空腹血糖(fasting blood glucose，FBG)；放射免疫分析法测定TNF-α、空腹血清胰岛素(fasting Insulin，FNS；计算胰岛素抵抗指数(HOMA-IR=FBGx FINS)／22.5)；肝组织匀浆生化测定MDA、SOD；电泳迁移率改变分析(EMSA)检测NF-KB活性；采用逆转录聚合酶链反应法(RT-PCR)检测PPARrmRNA；将肝组织用4℃生理盐水冲洗，在肝脏最大叶距边缘5mm处取小块肝组织，中性福尔马林固定，石蜡包埋，切片，HE染色，光镜下观察肝组织普通病理变化。另取1mm~3肝组织，2.5％戊二醛及1％锇酸双固定，梯度酒精脱水，环氧树脂包埋，超薄切片，HITACHI H7500透射电镜下观察肝细胞超微结构变化。
结果
1成功复制大鼠NASH模型。与空白模型组相比，电针组大鼠肝指数明显降低(P＜0.05)，炎症活动程度皆有明显改善(P＜0.05)；血清ALT、AST明显降低(P＜0.05)。除正常对照组外各组大鼠肝组织均表现有不同程度的脂肪变性、炎症、坏死。电针组肝组织脂肪变性及炎症程度明显减轻，肝组织形态结构改善。
2模型组血清TG、TC、FFA水平比正常组显著增高(P＜0.05)；模型组比电针组显著增高(P＜0.05)；电针组血清TG、TC水平较之药物组有下降趋势，但二者比较无明显差异(P＞0.05)；药物组血清FFA水平较之电针组有下降趋势，但二者比较无明显差异(P＞0.05)。
3模型组肝组织MDA含量显著高于正常组(P＜0.05)，SOD活性显著低于正常组(P＜0.05)；电针组与模型组比较，MDA含量显著降低(P＜0.05)，而SOD活性明显升高(P＜0.05)；电针组与药物组比较，MDA含量有下降趋势，有统4计学差异(P＜0.05)；而SOD活性有下降趋势，但无统计学差异(P＞0.05)。
4模型组血清TNF-α水平比正常组显著增高(P＜0.05)；电针组血清TNF-α水平比模型组显著降低(P＜0.05)；电针组血清TNF-α水平与药物组比较无明显差异(P＞0.05)。
5模型组胰岛素抵抗指数水平比正常组显著增高(P＜0.05)；模型组比电针组增高(P＜0.05)；电针组与药物组比较无明显差异(P＞0.05)。
6模型组和药物组的NF-KB活性明显高于正常对照组(P值均＜0.01)和电针组(P值均＜0.05)。模型组、电针组和药物组大鼠肝组织PPAR rmRNA的表达均较正常对照组有不同程度的减弱(P值均＜0.01)，模型组大鼠肝组织PPAR rmRNA的表达明显低于电针组(P＜0.01)。
结论氧化应激进而引起脂质过氧化和肝损伤，最终引起前炎症细胞因子产生，启动肝脏炎症反应；在NASH状态下NF-κB活性增强、PPAR rmRNA表达减弱，显示了三者之间的相关性。电针具有多靶位治疗NASH的作用：①电针能明显降低NASH大鼠肝指数，改善肝组织脂肪变性、炎症活动程度及肝功能。②电针能降低血清脂质水平、减轻FFA的肝脏毒性、改善肝脏对脂质代谢的调节、减轻肝脏炎症反应。③电针能够提高肝组织抗氧化能力，减轻脂质过氧化。④电针能降低TNF-α的表达，减少细胞因子相关性损害。⑤电针能改善NASH大鼠IR状态。⑥电针能够抑制NF-KB的活性、促进PPARrmRNA表达。电针治疗NASH的作用可能是通过腧穴-经络-脏腑相关性及神经-内分泌-免疫网络整体调节实现的。
Objective With the dramatic development of people's living standards, more and more people are suffering from non-alcoholic steatohepatitis or NASH as time goes by. Its mechanism is complex and still unknown. Several factors such as extra free fatty acids or FFA, oxidative stress, injuries caused by cytokines or CKs are considered to be pathologically relative.Some existed clinical and experimental researches have shown that steatohepatitis is in correlation with NF-κB as well as PPAR r, but pertinent literature is still not enough. It is necessary to do further research to clarity the relations between NASH and NF-κB as well as PPAR r. At present, it seems to be hard to choose some effective medications to treat NASH. TCM which has some predominances can be turned to concerning its treatment. According to his long term of clinical experiences, my tutor, professor Sun Guo-jie claimed that NASH might be caused by intaking excess fat and sweet foods for a long time, which lead to phlegm and blood stasis generating from within, constrained liver qi, heat caused by permanent stagnation, Yin deficiency due to internal heat. All in all, all these pathological factors lead to such a pathological characteristic as being insufficient in nature but the signs and symptoms are seemed to be excess. Its therapeutical principle should be supplementing the kidney and liver, strengthening the spleen and drain the excess water and phlegm, expelling the blood stasis. Pro. Sun Guo-jie chose Gan-shu acupoint, Zu Sanli acupoint, Feng Long acupoint and Tai Chong acupoint to treat NASH. We needled the acupoints mentioned above to treat patients who suffered NASH and gained significant effects concerning relieving the symptoms, improving the liver function, decreasing the blood fat and resisting fibrosis. In this research, we used classical animal models which are accepted worldwide, armed with the technologies in the fields of pathology, biochemistry, molecular biology, aiming to probe the activity of NF-κB and the expression of PPARrmRNA, make a clear explanation on the therapeutical mechanism of electric acupuncture on NASH in order to offer strong proofs for the clinical use of electric acupuncture in treating NASH.
Methods 48 SD rats were divided them into 2 groups, normal group with 12 rats and modeling group with 36 rats according to random digits table. The rats of the normal group were fed with common food;while the rats of the model group were fed with fat-rich diet, i.e,normal diet plus 13% lard oil and 2% cholesterol to rebuild NASH animal models according to the classical method offered by Fan Jian-gao. All the rats took food and drank water in a free way and the dairy staffs were changed on a daily basis. They were fed for 12 weeks in total. After 12 weeks, 2 rats of the normal group and 6 rats of the modeling group were picked out randomly. Pathological sections were made to show that animal model had been built successfully. Then the rest 30 rats of the modeling group were randomly divided into3 groups: model group, electric acupuncture group and the western Medicine group.The rats of both the normal group and the model group were treated as before continuously for another 4 weeks;the rats of the acupuncture group were punctured with electric acupuncture at such acupoints as Ganshu (BL 18), Zusanli (ST 36), Fenglong (ST 40) and Taichong (LR 3) bilaterally and also fed with a fat-rich diet continuously for another 4 weeks; the rats of the western medicine group were lavaged with UDCA 250mg/kg.d and also fed with a fat-rich diet continuously for another 4 weeks.All the rats were anesthetized with 2% Pentobarbitalum Natricum through peritoneal injection with a regular standard dose after a night at the end of the 16th week. Blood was collected from the inferior vena and Serum was separated with regular methods. The weight, appetite, behavior, state,hair and death rate of the rats were closely observed.Liver index numbers were calculated by humid weight/body weight x 100%.Serum alanine aminotransferase or ALT, aspartate aminotransferase or AST, triglyceride or TG, total cholesterol or TC, Free fatty acid or FFA, fasting blood glucose or FBG were tested through Olympus Au560 Automatic biochemistry analyzer. Tumor necrosis factor-αor TNF-αand fasting Insulin or FINS were tested by radio immunoassay.As a result, Insulin resistance index or IR index could be calculated through the formula of FBGx FINS/22.5. Fresh liver tissue was made into tissue homogenate. Malondialdehyde or MDA and superoxide dismutase or SOD were tested by way of tissue homogenate biochemistry. NF-kappa B Binding Activity detected by electrophoretic mobiLity shift assay (EMSA): According to the procedure in the manual of the kits, took 1.75μmol/L unlabelled double-stranded oligonucleotide probe, T4polynucleotide kinase 1μ1,γ_~(32)p ATP (0.37 GBq/ml) 1μ1 to llabel. Took 20μg ribonucleoprotein and put into 10μl gel retardation binding buffer 10mINS at 37℃, added 1μ1~(32)p-labelled oligonucleotide probe 30miNS at 37℃, then carried out 6% native polyacrylamide gel electrophoresis and autoradiography 72 hs after gel vaccum dehydration, Observed the results and gray scale scanning was carried out with BIO-PROFIL image analysis system, assayed coloration positive area in comparison with the background negative area and calculated the mean gary scale values. PPAR rmRNA was detected by RT-PCR. Part of the liver tissues were flushed with 4℃normal saline and small scraps of liver tissues were taken at a farmost distance of 5mm to the rim of the liver lobes.Histological specimens were stained with HE after being fixated with 10% netural Formalin and made into slices buried in Paraffin and then studied. 1 mm~3 Hepatic slices were fixed with 2.5% Glutaric Dialdehyde and 1% osmic acid and stained with plumbum and uranium and the ultrastructures of the liver tissues was observed through HITACHI H7500 electron microscope.
Results
1 NASH animal models were replicated successfully. In comparison to the rats of model group, the body weight number of the rates of the normal group were significantly decreased (P<0.05); so were serum ALT and AST.Steatosis, inflammation,necrosis and fibrosis were present in the livers of the rats of all the modelling groups, and were most severe in the liver tissues of the rats of the model group while the conditions mentioned above were significantly improved in the livers of the rates of the electric acupuncture group. The morphosis of the hepatic tissues of the rats of the electric acupuncture group were markedably improved.
2 The serum TG, TC and FFA contents were markedly higher in the model group than those of the normal group (P<0.05); There was also a significant difference between the model group and the electric acupuncture group (P<0.05); Concerning the serum TG and TC contents, there was a downward trend in the electric acupuncture group compared with the western medicine group, but there was no difference between them (P>0.05); Concerning the serum FFA contents, there was a downward trend in the western medicine group compared with the electric acupuncture group, but there was no difference between them (P>0.05).
3 The MDA contents were markedly higher in the model group than those of the normal group (P<0.05); The MDA contents were markedly lower in the model group than those of the normal group (P<0.05); The MDA and SOD contents were markedly lower and higher respectively in the livers of the electrnic acupuncture group in comparison to the livers of the model group (P<0.05); There was a significant difference between the electric acupuncture group and the western medicine group concerning the MDA contents (P<0.05);Regarding the SOD contents,there was a downward trend in the livers of the electric acupuncture group, but there was no significant difference between the electric acupuncture group and the western medicine group (P>0.05).
4 The serum TNF-αcontents were markedly higher in the model group than those of the normal group (P<0.05); There was also a significant difference between the model group and the electric acupuncture group (P<0.05); Concerning the serum TNF-αcontents, there was a downward trend in the western medicine group, but there was no difference between the electric acupuncture group and the western medicine group (P>0.05).
5 Concerning the IR levels, IR levels were markedly higher in the model group than those of the normal group (P<0.05); There was also a significant difference between the model group and the electric acupuncture group (P<0.05); there was a downward trend in the western medicine group, but there was no difference between the electric acupuncture group and the western medicine group (P>0.05).
6 NF-kappa B binding activity was obviously higher in the model group and the western medicine group than those in the normal group (P<0.01) and the electric acupuncture group(P<0.05).The expression of P P A RrmRNA of the model group, electric group and western medicine group was weaker than that of the normal group (P<0.01) and the level of P P A RrmRNA was lower in the livers of the model group than that of electric acupuncture group(P<0.01).
Conclusion Oxidative stress can leads to lipid peroxidation and hepatic injuries as well. In the end, it can cause the appearance of the pre-inflammatory cell factors which might initiate inflammatory reactions in the liver.In the state of NASH, NF-kappa B binding activity will be significantly enhanced while the levels of the expression of PPAR rmRNA will be lowered, which shows the correlatin among NASH, NF-kappa B binding activity and PPAR rmRNA. Electric acupuncture can be used to treat NASH at multiple target sites:It can decrease the liver index of the rats, improve adipoe degeneration, inflammation degree and liver function; it can lower serum lipid, decrese the hepatotoxity caused by FFA, improve the regulation of liver on the metabolim of lipid, relieve the inflammatory reaction; it can strengthen the hepatic tissues against oxidation,relieve lipid peroxidation; it can decrease the expression of TNF-αand as a result it can decrease the injuries caused by cytokines; it can inhibit the binding activity of NF-KB and promote the expression of PPARrmRNA. It is a possibility that electric acupuncture can be used as a therapeutical method in treating NASH through such two ways as the correlaton among acupoints, channels and collaterals and visceras as well as the interaction between nerve, endocrine and immunological network.
方法将48只SD大鼠称重标记后按随机数字表随机分为2组：正常对照组12只；造模组36只。正常对照组采用普通饲料喂养；造模组采用高脂饲料喂养。实验依据范建高经典造模方法(标准饲料的基础上加2％胆固醇、13％猪油)复制NASH动物模型。12周后，从正常对照组随机抽取2只，造模组随机抽取6只，肝脏病理切片证实造模成功后，取剩余30只造模组大鼠称重，再随机分为模型组10只，电针组10只，药物组10只。正常组不进行电针和药物治疗，同前普通饲料喂养4周；模型对照组，不进行电针和药物治疗，同前高脂饲料喂养4周。针刺组取穴参照新世纪全国高等中医药院校规划教材《实验针灸学》大鼠针灸穴位定位方法及拟人比照法定位，选取双侧肝俞、足三里、丰隆、太冲，自第12周开始每天治疗1次，连续6天后休息1天，共治疗4周；药物组，自第12周开始每天以西药熊去氧胆酸(UDCA)250mg／kg．d的水溶液灌胃，继前高脂饲料喂养4周。各组大鼠在实验第16周隔夜空腹以2％戊巴比妥钠按2ml／kg量麻醉，经下腔静脉采血，迅速按常规分离血清；摘取肝脏。观察动物体重、食欲、行为、状态、毛发及死亡情况，计算肝指数(肝脏湿重／体重×100％)；采用Olympus Au560全自动生化分析仪测定血清ALT、AST、TG、TC、FFA、空腹血糖(fasting blood glucose，FBG)；放射免疫分析法测定TNF-α、空腹血清胰岛素(fasting Insulin，FNS；计算胰岛素抵抗指数(HOMA-IR=FBGx FINS)／22.5)；肝组织匀浆生化测定MDA、SOD；电泳迁移率改变分析(EMSA)检测NF-KB活性；采用逆转录聚合酶链反应法(RT-PCR)检测PPARrmRNA；将肝组织用4℃生理盐水冲洗，在肝脏最大叶距边缘5mm处取小块肝组织，中性福尔马林固定，石蜡包埋，切片，HE染色，光镜下观察肝组织普通病理变化。另取1mm~3肝组织，2.5％戊二醛及1％锇酸双固定，梯度酒精脱水，环氧树脂包埋，超薄切片，HITACHI H7500透射电镜下观察肝细胞超微结构变化。
结果
1成功复制大鼠NASH模型。与空白模型组相比，电针组大鼠肝指数明显降低(P＜0.05)，炎症活动程度皆有明显改善(P＜0.05)；血清ALT、AST明显降低(P＜0.05)。除正常对照组外各组大鼠肝组织均表现有不同程度的脂肪变性、炎症、坏死。电针组肝组织脂肪变性及炎症程度明显减轻，肝组织形态结构改善。
2模型组血清TG、TC、FFA水平比正常组显著增高(P＜0.05)；模型组比电针组显著增高(P＜0.05)；电针组血清TG、TC水平较之药物组有下降趋势，但二者比较无明显差异(P＞0.05)；药物组血清FFA水平较之电针组有下降趋势，但二者比较无明显差异(P＞0.05)。
3模型组肝组织MDA含量显著高于正常组(P＜0.05)，SOD活性显著低于正常组(P＜0.05)；电针组与模型组比较，MDA含量显著降低(P＜0.05)，而SOD活性明显升高(P＜0.05)；电针组与药物组比较，MDA含量有下降趋势，有统4计学差异(P＜0.05)；而SOD活性有下降趋势，但无统计学差异(P＞0.05)。
4模型组血清TNF-α水平比正常组显著增高(P＜0.05)；电针组血清TNF-α水平比模型组显著降低(P＜0.05)；电针组血清TNF-α水平与药物组比较无明显差异(P＞0.05)。
5模型组胰岛素抵抗指数水平比正常组显著增高(P＜0.05)；模型组比电针组增高(P＜0.05)；电针组与药物组比较无明显差异(P＞0.05)。
6模型组和药物组的NF-KB活性明显高于正常对照组(P值均＜0.01)和电针组(P值均＜0.05)。模型组、电针组和药物组大鼠肝组织PPAR rmRNA的表达均较正常对照组有不同程度的减弱(P值均＜0.01)，模型组大鼠肝组织PPAR rmRNA的表达明显低于电针组(P＜0.01)。
结论氧化应激进而引起脂质过氧化和肝损伤，最终引起前炎症细胞因子产生，启动肝脏炎症反应；在NASH状态下NF-κB活性增强、PPAR rmRNA表达减弱，显示了三者之间的相关性。电针具有多靶位治疗NASH的作用：①电针能明显降低NASH大鼠肝指数，改善肝组织脂肪变性、炎症活动程度及肝功能。②电针能降低血清脂质水平、减轻FFA的肝脏毒性、改善肝脏对脂质代谢的调节、减轻肝脏炎症反应。③电针能够提高肝组织抗氧化能力，减轻脂质过氧化。④电针能降低TNF-α的表达，减少细胞因子相关性损害。⑤电针能改善NASH大鼠IR状态。⑥电针能够抑制NF-KB的活性、促进PPARrmRNA表达。电针治疗NASH的作用可能是通过腧穴-经络-脏腑相关性及神经-内分泌-免疫网络整体调节实现的。
Objective With the dramatic development of people's living standards, more and more people are suffering from non-alcoholic steatohepatitis or NASH as time goes by. Its mechanism is complex and still unknown. Several factors such as extra free fatty acids or FFA, oxidative stress, injuries caused by cytokines or CKs are considered to be pathologically relative.Some existed clinical and experimental researches have shown that steatohepatitis is in correlation with NF-κB as well as PPAR r, but pertinent literature is still not enough. It is necessary to do further research to clarity the relations between NASH and NF-κB as well as PPAR r. At present, it seems to be hard to choose some effective medications to treat NASH. TCM which has some predominances can be turned to concerning its treatment. According to his long term of clinical experiences, my tutor, professor Sun Guo-jie claimed that NASH might be caused by intaking excess fat and sweet foods for a long time, which lead to phlegm and blood stasis generating from within, constrained liver qi, heat caused by permanent stagnation, Yin deficiency due to internal heat. All in all, all these pathological factors lead to such a pathological characteristic as being insufficient in nature but the signs and symptoms are seemed to be excess. Its therapeutical principle should be supplementing the kidney and liver, strengthening the spleen and drain the excess water and phlegm, expelling the blood stasis. Pro. Sun Guo-jie chose Gan-shu acupoint, Zu Sanli acupoint, Feng Long acupoint and Tai Chong acupoint to treat NASH. We needled the acupoints mentioned above to treat patients who suffered NASH and gained significant effects concerning relieving the symptoms, improving the liver function, decreasing the blood fat and resisting fibrosis. In this research, we used classical animal models which are accepted worldwide, armed with the technologies in the fields of pathology, biochemistry, molecular biology, aiming to probe the activity of NF-κB and the expression of PPARrmRNA, make a clear explanation on the therapeutical mechanism of electric acupuncture on NASH in order to offer strong proofs for the clinical use of electric acupuncture in treating NASH.
Methods 48 SD rats were divided them into 2 groups, normal group with 12 rats and modeling group with 36 rats according to random digits table. The rats of the normal group were fed with common food;while the rats of the model group were fed with fat-rich diet, i.e,normal diet plus 13% lard oil and 2% cholesterol to rebuild NASH animal models according to the classical method offered by Fan Jian-gao. All the rats took food and drank water in a free way and the dairy staffs were changed on a daily basis. They were fed for 12 weeks in total. After 12 weeks, 2 rats of the normal group and 6 rats of the modeling group were picked out randomly. Pathological sections were made to show that animal model had been built successfully. Then the rest 30 rats of the modeling group were randomly divided into3 groups: model group, electric acupuncture group and the western Medicine group.The rats of both the normal group and the model group were treated as before continuously for another 4 weeks;the rats of the acupuncture group were punctured with electric acupuncture at such acupoints as Ganshu (BL 18), Zusanli (ST 36), Fenglong (ST 40) and Taichong (LR 3) bilaterally and also fed with a fat-rich diet continuously for another 4 weeks; the rats of the western medicine group were lavaged with UDCA 250mg/kg.d and also fed with a fat-rich diet continuously for another 4 weeks.All the rats were anesthetized with 2% Pentobarbitalum Natricum through peritoneal injection with a regular standard dose after a night at the end of the 16th week. Blood was collected from the inferior vena and Serum was separated with regular methods. The weight, appetite, behavior, state,hair and death rate of the rats were closely observed.Liver index numbers were calculated by humid weight/body weight x 100%.Serum alanine aminotransferase or ALT, aspartate aminotransferase or AST, triglyceride or TG, total cholesterol or TC, Free fatty acid or FFA, fasting blood glucose or FBG were tested through Olympus Au560 Automatic biochemistry analyzer. Tumor necrosis factor-αor TNF-αand fasting Insulin or FINS were tested by radio immunoassay.As a result, Insulin resistance index or IR index could be calculated through the formula of FBGx FINS/22.5. Fresh liver tissue was made into tissue homogenate. Malondialdehyde or MDA and superoxide dismutase or SOD were tested by way of tissue homogenate biochemistry. NF-kappa B Binding Activity detected by electrophoretic mobiLity shift assay (EMSA): According to the procedure in the manual of the kits, took 1.75μmol/L unlabelled double-stranded oligonucleotide probe, T4polynucleotide kinase 1μ1,γ_~(32)p ATP (0.37 GBq/ml) 1μ1 to llabel. Took 20μg ribonucleoprotein and put into 10μl gel retardation binding buffer 10mINS at 37℃, added 1μ1~(32)p-labelled oligonucleotide probe 30miNS at 37℃, then carried out 6% native polyacrylamide gel electrophoresis and autoradiography 72 hs after gel vaccum dehydration, Observed the results and gray scale scanning was carried out with BIO-PROFIL image analysis system, assayed coloration positive area in comparison with the background negative area and calculated the mean gary scale values. PPAR rmRNA was detected by RT-PCR. Part of the liver tissues were flushed with 4℃normal saline and small scraps of liver tissues were taken at a farmost distance of 5mm to the rim of the liver lobes.Histological specimens were stained with HE after being fixated with 10% netural Formalin and made into slices buried in Paraffin and then studied. 1 mm~3 Hepatic slices were fixed with 2.5% Glutaric Dialdehyde and 1% osmic acid and stained with plumbum and uranium and the ultrastructures of the liver tissues was observed through HITACHI H7500 electron microscope.
Results
1 NASH animal models were replicated successfully. In comparison to the rats of model group, the body weight number of the rates of the normal group were significantly decreased (P<0.05); so were serum ALT and AST.Steatosis, inflammation,necrosis and fibrosis were present in the livers of the rats of all the modelling groups, and were most severe in the liver tissues of the rats of the model group while the conditions mentioned above were significantly improved in the livers of the rates of the electric acupuncture group. The morphosis of the hepatic tissues of the rats of the electric acupuncture group were markedably improved.
2 The serum TG, TC and FFA contents were markedly higher in the model group than those of the normal group (P<0.05); There was also a significant difference between the model group and the electric acupuncture group (P<0.05); Concerning the serum TG and TC contents, there was a downward trend in the electric acupuncture group compared with the western medicine group, but there was no difference between them (P>0.05); Concerning the serum FFA contents, there was a downward trend in the western medicine group compared with the electric acupuncture group, but there was no difference between them (P>0.05).
3 The MDA contents were markedly higher in the model group than those of the normal group (P<0.05); The MDA contents were markedly lower in the model group than those of the normal group (P<0.05); The MDA and SOD contents were markedly lower and higher respectively in the livers of the electrnic acupuncture group in comparison to the livers of the model group (P<0.05); There was a significant difference between the electric acupuncture group and the western medicine group concerning the MDA contents (P<0.05);Regarding the SOD contents,there was a downward trend in the livers of the electric acupuncture group, but there was no significant difference between the electric acupuncture group and the western medicine group (P>0.05).
4 The serum TNF-αcontents were markedly higher in the model group than those of the normal group (P<0.05); There was also a significant difference between the model group and the electric acupuncture group (P<0.05); Concerning the serum TNF-αcontents, there was a downward trend in the western medicine group, but there was no difference between the electric acupuncture group and the western medicine group (P>0.05).
5 Concerning the IR levels, IR levels were markedly higher in the model group than those of the normal group (P<0.05); There was also a significant difference between the model group and the electric acupuncture group (P<0.05); there was a downward trend in the western medicine group, but there was no difference between the electric acupuncture group and the western medicine group (P>0.05).
6 NF-kappa B binding activity was obviously higher in the model group and the western medicine group than those in the normal group (P<0.01) and the electric acupuncture group(P<0.05).The expression of P P A RrmRNA of the model group, electric group and western medicine group was weaker than that of the normal group (P<0.01) and the level of P P A RrmRNA was lower in the livers of the model group than that of electric acupuncture group(P<0.01).
Conclusion Oxidative stress can leads to lipid peroxidation and hepatic injuries as well. In the end, it can cause the appearance of the pre-inflammatory cell factors which might initiate inflammatory reactions in the liver.In the state of NASH, NF-kappa B binding activity will be significantly enhanced while the levels of the expression of PPAR rmRNA will be lowered, which shows the correlatin among NASH, NF-kappa B binding activity and PPAR rmRNA. Electric acupuncture can be used to treat NASH at multiple target sites:It can decrease the liver index of the rats, improve adipoe degeneration, inflammation degree and liver function; it can lower serum lipid, decrese the hepatotoxity caused by FFA, improve the regulation of liver on the metabolim of lipid, relieve the inflammatory reaction; it can strengthen the hepatic tissues against oxidation,relieve lipid peroxidation; it can decrease the expression of TNF-αand as a result it can decrease the injuries caused by cytokines; it can inhibit the binding activity of NF-KB and promote the expression of PPARrmRNA. It is a possibility that electric acupuncture can be used as a therapeutical method in treating NASH through such two ways as the correlaton among acupoints, channels and collaterals and visceras as well as the interaction between nerve, endocrine and immunological network.
引文
1. Fan JS, Zhuang H, Li YG, et al. Serotyping and genotyping of hepatitits B among HBsAg positive and negative hepatitis B patients in 8 cities of China. Zhonghua Weishengwuxue He Mianyixue Zazhi, 1998, 18:88-91.
2．范建高，曾民德，李继强，等．Bezafibrate对大鼠高脂血症和脂肪肝形成的影响．胃肠病学和肝病学杂志，1999，8(2)：100-102．
3．李忠仁．实验针灸学．北京：中国中医药出版社，2003：327-329．
4．孙璇，李学武．天灸对大鼠脂肪肝治疗作用的实验研究．北京中医药大学学报，2001，24(1)：48．
5．林文注．实验针灸学．上海：上海科学技术出版社，1994．
6．朱军，范建高，方继伟．东宝肝泰对大鼠高脂饮食脂肪性肝炎的预防作用．现 代医药卫生，2003，19(8)：951．
7.Blechacz B, Stremmel W. NASH - nonalcoholic steatohepatitis. Z Gastroenterol. 2003 Jan; 41(1):77-90.
8.DayC, James.Steatohepatitis: a tale of two " hits " . Gastroenterology,1998,114(4):842 845.
9．陆伦根，曾民德．改善胰导素抵抗在非酒精性脂肪性肝病防治中的作用．中华肝脏病杂志，2003，11(2)：113．
10．范建高，曾民德．脂肪性肝病．北京：人民卫生出版社，2005，336-337．
11.Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001; 21(1):3-16.
12.Bahrami H, Daryani NE, MIRmomen S, et al. Clinical and histological features of nonalcoholic steatohepatitis in IRanian patients. BMC Gastroenterol. 2003 Oct 16; 3(1):27.
13.Gramlich T, Kleiner DE, McCullough A J, et al. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol. 2004 Feb; 35(2):196-199.
14．范建高，曾民德．脂肪性肝病．北京：人民卫生出版社，2005，116．
15．胡坚文．中医对脂肪肝的认识和治疗探讨．湖北中医杂志，1998，20(3)：12
16．徐春军．肝、胆、胰疾病的针灸治疗．国外医学中医中药分册，1997，19(1)：51．
17．李洁，许佳年，张琴．针药结合治疗脂肪肝32例临床观察．湖南中医药导报，1999，6(5)：17-18．
1．范竹萍．非酒精性脂肪性肝炎研究进展[J]国外医学消化分册，1998，18：20
2.Chitturi S, Farrell GC.Etio-pathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis.2001,21 (1):27-41.
3．历有名，夏维新．脂肪肝现代诊疗．江苏科学技术出版社．第Ⅰ版．2003，1：2233．
4.Day CP, James OFW I Steatohepatitis: a tale of two hit s? [J] 1 Gast roen-terology, 1998, 114: 842.
5.Galdwell SH,hespenheide EE.Subacute Liver FaiLure in obese women[J].AM J Gastruenterology.2001,97(8):2058-2062.
6.Wanless IR., Shiota K .The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases:a four-step model including the role of lipid release and he-patic venular obstruction in the progression tocIRrhosis. Semin Liver Dis. 2004,24 ( 1 ) :99-106.
7.Bradbury MW, Berk PD.Lip id metabolism in hepatic steatosis. Clin Liver Dis. 2004,8(3):639-671.
8.Marchesini G, Bugianesi E, Foflani G, et al. Nonalcoholic fatty liver, steato-hepatitis, and the metabolic syndrome. Hepatology. 2003 Aug; 38(2):536.
9.Poniachik J, ManclLla C, Contreras J,et al. [Obesity: risk factor for steatohepati-tis and hepatic fibrosis] Rev Med ChlL. 2002 Jul;130(7):731-736.
10. Welt man MD, Farrell GC, Liddle C 1 Increased hepatocyte CYP2 El expression in a rat nutritional model of hepatic steatosis wit h inflammation [J] 1 Gastroen-terology, 1996, 111: 1645
11. Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and moblLization in the pathogenesis of Insulin resistance and type 2 diabetes. Endocr Rev 2002;23:201-229.
12. Duseja A, Murlidharan R, Bhansali A, et al. Assessment of Insulin resistance and effect of metformin in nonalcoholic steatohepatitis--a preliminary report. Indian J Gastroenterol. 2004 ,23(1):12-15.
13. Fromenty B, Robin MA, IgoudjIL A, et al. The INS and outs of mitochondrial dysfunction in NASH. Diabetes Metab 2004;30:121-138.
14. Chitturi S, Farrell GC.Etio-pathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis.2001; 21 (1) :27-41.
15. Mavrelis PG, Ammon HV, GleysteenJJ, et al . Hepatic free fattyacids in alcoholic liver disease and morbid obesity. Hepatology, 1983, 3: 226-231.
16. Day CP, James OF. Hepatic steatosis: Innocent bystander- or guILt ypart y? Hepatology, 1998, 27: 1463-1466.
17. Emery MQ Fisher JM, Chien JYCYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology. 2003 Aug;38(2):428-35.
18. Lieber CS.CYP2E1: from ASH to NASH. Hepatol Res. 2004 Jan;28(1): 1-11.
19. Cytochrome P-450 enzymes and oxidative stress.' Am J Physiol Gastrointest Liver Physiol. 2001Nov;281 (5) :1135-1139.
1. ChitturiS, Farrell GC.Etio-pathogenesis of nonalcoholicsteatohepatitis. Semin Liver Dis.2001; 21(1):27-41.
2. Chitturi S, and Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis, 2001[iSi]21: 29-40.
3. Mehta K, Van Thiel DH, Shah N, et al. Nonalcoholic fatty liver disease: patho- genesis and the role of antioxidants. Nutr Rev. 2002 Sep; 60(9):289-293.
4. YANG, ZHUH, LiH, et al. Mitochondrial adaptations to obesity related oxidant stress[J]. Arch Bio-chem Biophys, 2000,378(2):259 268.
5. Prandota J. important role of prodromal viRal infections responsible for inhibi- tion of xenobiotic metabolizing enzymes in the pathomechanism of idiopathic Reye's syndrome, Stevens-Johnson syndrome, autoimmune hepatitis, and hepato- toxicity of the therapeutic doses of acetaminophen used in genetically predis- posed persons. Am J Ther,2002 Mar-Apr;9(2): 149-156.
6. Gochee PA, Jonsson JR, Clouston AD, et al. Steatosis in chronic hepatitis C: as- sociation with increased messenger RNA expression of collagen i, tumor necrosis factor-alpha and cytochrome P450 2E1. J Gastroenterol Hepatol. 2003 Apr; 18(4):386-392.
7. George D K,Goldwurm S,Macdonald G A,et al.Lncreased hepatic IRon concen- tration in nonalcoholic steatohepatitis is associated with increased fibro- sis. Gastroenterology, 1998; 114:311 - 318.
8. Turlin B,Mendler MN,MoiRand R, et al.Histologic features of the liver in Insulin resistance associated IRon overloasd [J].AmJ Cin pathol, 2001,116(1):263-270.
9.AnghlLei LJ,Esposito M,Fulcheri E,et al.IRon-ethanol synergism and pathologi- cal liver transformation.in Vivo, 1999; 13:13-20
10.Younossi ZM,Gramlich T,Bacon BR,et al.Hepatic IRon and nonalcoholic fatty liver disease,Heptology, 1999;30:847-850
11.Videla LA, Rodrigo R, Araya J, et al. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med. 2004 Nov 1 ;37(9): 1499-507.
12.Perez-Carreras M, Del Hoyo P, Martin MA, et al. Defective hepatic mitochondrial respiRatory chain in patients with nonalcoholic steatohepatitis. Hepatology. 2003 Oct;38(4):999-1007.
13.Robertson G; Leclercq i, Farrell GC. Nonalcoholic steatosis and steatohepatitis, ii. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol. 2001 Nov; 281 (5): 1135-1139.
14.Fromenty B, Robin MA, igoudjlL A, et al. The INS and outs of mitochondrial dysfunction in NASH. Diabetes Metab. 2004 Apr;30(2): 121-138.
15.Muller T, Langner C, Fuchsbichler A, et al. immunohistochemical analysis of Mallory bodies in WILsonian and non-WILsonian hepatic copper toxicosis. Hepatology. 2004 Apr;39(4):963-969.
16.Leclercq iA, Farrell GC, Field J, Bell D, et al. CYP2E1 and CYP4A as micro- somal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J Clin invest, 2000,105:1067-1075.
17.Sanyal, AJ, Campbell-Sargent C, MIRshahi F, et al. Nonalcoholic steatohepatitis: association of Insulin resistance and mitochondrial abnormalities. Gastroenterol-ogy, 2001,120: 1183-1192.
18．王玉堂，安华．针刺丰隆穴降血脂47例临床观察[J]．中国针灸，1990，(3)：21．
19．许玉民．针刺对缺血性中风血脂变化的观察．上海针灸杂志，1992，11(2)：13．
20．伦新，荣莉．足三里、关元穴隔姜灸对老年人SOD、T细胞亚群的影响[J]．新中医，1999，6(6)：24．
21．孔立红，陈友梅，郭桂荣，等．针灸对糖尿病大鼠血清SOD及MDA的影响及其比较研究[J]．中国针灸，1998，17(4)：42-43．
22．刘庆忠，郑灏泳．针刺对小鼠CAT、GSH-PX活性的影响[J]．针灸临床杂志，2001，17(4)：51-52．
23．孙忠人，赵英，毕克滨，等．足三里抗衰老作用的实验研究[J]．针灸临床杂志，1996，12(2)：33．
1. Rouach H, Fataccioli V, GentlL M, et al.Effect of Chronic ethanol feeding on lipid peroxidation and protein oxidation i radiation to liver pathology. Hepatology, 1997, 25:35.
2. Fan JS, Zhuang H, Li YG, et al. Serotyping and genotyping of hepatitits B among HBsAg positive and negative hepatitis B patients in 8 cities of China. Zhonghua Weishengwuxue He Mianyixue Zazhi, 1998,18:88-91
3． 彭亚琴，彭利，徐松菊，等．活血化瘀、化痰利湿法对大鼠肥胖相关性脂肪肝的作用．华中医学杂志．2004，28(1)：21．
4. Herbert T, Anna M. Cytokines in alcoholic and nonalcoholic steato hepatitis. N EnglMed, 2000, 343: 1467.
5. Craig J, ShlRish B, ion D, et al . Cytokines in alcoholic liver disease.Semin LiverDis, 1999, 19: 2052-2219.
6． 顾长海，王宇明．肝功能衰蝎北京：人民卫生出版社，2002：51．
7. wiggat Roberts, Dymock RB,et al..The role of mall.intestimal bacterial over- growth and tumor necrosis factor- a in the pathogenesis of nonalcoholic steato- hepatitjs[J].Gut, 2001,48(2):206.
8. Day CRNASH-related Liver FaiLure:One hit too many?[J].Am J Gastroenterol-ogy,2001,97: 1872-1874.
9. RibelRo PS, Cortez-Pinto H, Sola S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and al- coholic steatohepatitis patients. Am J Gastroenterol. 2004 Sep;99(9): 1708-1717.
10. Pessayre D, Berson A, Fromenty B, et al. Mitochondria in steatohepatitis. Semin Liver Dis, 2001,21: 57-69,.
11. Magnusson C, Vaux DL. Signalling by CD95 and TNF receptors: not only life and death, immunol Cell Biol 1999;77:41-46.
1. Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic Insulin resistance in non-alcoholic fatty liver disease. J Biol Chem, 2004, 279:32345-32353
2. Kanauchi M. A new index of Insulin sensitivity obtained from the oral glucose tolerance test applicable to advanced type 2 diabetes. Diabetes Care, 2002,25:1891-1892
3． 陆伦根，曾民德．改善胰导素抵抗在非酒精性脂肪性肝病防治中的作用．中华肝脏病杂志，2003，11(2)：113．
4． 陈卫星，虞朝辉，厉有名，等．非酒精性脂肪肝与胰岛素抵抗及糖代谢异常的关系．中华肝脏病杂志，2000，8(2)：76-77．
5. LeroyP, DessolinS, VILlageois P, etal.JBiolChem, 1996, 271:2365-2368.
6. Kolaczyski J W, Nyce M R, Considine RV, et al.Diabetses, 1996, 45:699-701.
7. Lee K N, Jeong i C, Lee S J, et al. Regulation ofleptin gene expression- byInsulin and growth hormone in mouse adipocytes[J]. Exp Mol Med, 2001, 33:234 239.
8. Lee J W, Romsos DR. Leptin deficient mice commence hypersecreting Insulin in response to acetylcholine between 1 and 2 weeks of age[J]. Exp Biol Med(May wood), 2001, 226:906 911.
9. Timothy J, Scott Heller R, Colin AL, et al. Leptin suppression of Insulin secretion by the activation of ATP-sensitive K~+ channels in pancreatic-cells[J].Dia betes, 1997, 46:1087 1093.
10． 刘志诚，孙凤岷，等．针刺对肥胖大鼠瘦素水平和瘦素受体基因表达的作用．Chinese Acupuncture&Moxibustio．2003：7(23)412-414．
1. Fan JS, Zhuang H, Li YG, et al. Serotyping and genotyping ofhepatitits B among HBsAg positive and negative hepatitis B patients in 8 cities of China. Zhonghua Weishengwuxue He Mianyixue Zazhi, 1998,18:88-91
2． 范建高曾民德李继强等．Bezafibrate对大鼠高脂血症和脂肪肝形成的影响．胃肠病学和肝病学杂志，1999，8(2)：100-102．
3. Stuyver L, De Gendt S, Van Geyt C, et al. A new genotype of hepatitis B viRus: Complete genome and Phylogenetic relatedness. J BenvlRol,2000,81 (Pt 1):67-74.
4. Rouach H, Fataccioli V, GentIL M, et al.Effect of Chronic ethanol feeding on lipid peroxidation and protein oxidation radiation to liver pathology. Hepatology, 1997, 25:35.
5． 范建高，曾民德．脂肪肝．上海：上海医科大学出版社，2000．204．
6． 郭留芹，姜春萌，王朝晖．柴胡、丹参复方对非酒精性脂肪肝大鼠的干预．中国临床康复，2006，10(15)：117．
7. Han C, Demetris AJ, Michalopooulos G, et al. 85-kDa cPLA plays a critical role in PPAR-mediated gene transcription in human hepatoma cells. Am J Physiol Gastrointest Liver Physiol, 2002, 282:586-597.
8. Everett L, Galli A, Crabb D. The role of hepatic peroxisome proliferator-actived receptors in health and disease. Liver, 2000, 20:191-199.
9. Bradbury MW, Berk PD. Lipid metabolism in hepatic steatosis, lin Liver Dis, 2004,8:639-671.
10. Sung CK, She H, Xiong S, et al. Tumor necrosiss factor-alpha inhibits perox- isome proliferator-actived receptor gamma activity at a posttranslational level in hepatic stellate cells. Am J Physio Gastrointest Liver Physiol, 2004,286:722-729.
11． 赵彩彦，王建彬，邓卓军，等．大鼠肝组织核因子-kB活性变化与PPAr表达的关系．中华肝脏病杂志．2005，13(2)96-100．
1．李正全，庞佑清．中医肝胆病证学．人民卫生出版社．第一版．2003，2：320．
2．徐列明，胡义扬，曾民德．脂肪性肝病．北京：人民卫生出版社，2005，537．
3．范建高，曾民德．脂肪性肝病．北京：人民卫生出版社，2005，538-539．
4．骆传佳，何启会，蒋大春，等．辨证与辨病相结合治疗非酒精性脂肪性肝炎的临床观察．中西医结合肝病杂志，2004，14(5)：274．
5．范建高，徐正婕．美国非酒精性脂肪肝病的诊断与共识．肝脏．2003，8(1)：58．
6．北京中医医院编．关幼波临床经验选．人民卫生出版社，1979：98．
7．姚国科，乔爱萍．辨证治疗脂肪肝46例．中国医药学报，1995，10(6)：31．
8．杨建辉．林鹤和治脂肪肝的经验．江西中医药，2000，31(3)：1．
9．徐列明，胡义扬，曾民德．脂肪性肝病．北京：人民卫生出版社，2005，537-539
10．王凤珍，杨钦河，王强，等．中医药治疗脂肪肝临床研究进展．安徽中医学院学报，2006，25(1)：53．
11．杨一明，靳瑞，张家维．针刺对高脂血症患者高密度脂蛋白亚组分和其他脂质含量的影响[J]．针灸学报，1992，(1)：7．
12．周杰芳，冼志红．针刺对高血脂病人的血脂及血液流变学影响的临床观察．广西中医药，1994；17(3)：39．
13．王玉琴，甄薇，李黎斌，等．针刺对高胆固醇血症家兔影响的研究．中国针灸，1994；14(2)：32．
14．黄为敏，黄坤厚，徐青燕，等．电针对内毒素休克大鼠肝脏的影响)))组织化学观察．针刺研究，1995；20(3)：53．
15．王威，于红，朴顺福，等．电针足三里穴对酒精性脂肪肝大鼠模型的影响．中国针灸，2004，24(12)：857-858．
16．解秸萍，李晓泓，李蔚，等．丰隆穴化痰作用及机制探讨．针灸临床杂志，2006，22(1)：1-2．
17．解秸萍，李晓泓，张露芬，等．针刺不同穴位对高脂血症大鼠血脂影响的实验研究．北京中医药大学学报，2003，26(5)：83．
18．胡卫东，杨浩明，郑高坪，等．针灸治疗非酒精性脂肪性肝炎临床观察．广州中医药大学学报，2006，23(1)：39-40．
19．王玉堂，安华．针刺丰隆穴降血脂47例临床观察[J]．中国针灸，1990，(3)：21．
20．刘晓辉．当归维生素B12混合穴位注射治疗高脂血症56例[J]时珍国医国 药，2001，12(4)：360．
21．徐春军．肝、胆、胰疾病的针灸治疗．国外医学中医中药分册，1997，19(1)：51．
22．孙璇，李学武．天灸对大鼠脂肪肝治疗作用的实验研究．北京中医药大学学报，2001，24(1)：48-50．
23．程井军，吴其恺，贺劲松，等．电针治疗非酒精性脂肪性肝炎的临床观察．湖北．中医杂志，2005，27(8)：11．
24．陈邦国．针刺对青壮年脑动脉硬化病人血脂的影响．河南中医，1998，18(1)：36-37．
25．程井军，吴其恺，贺劲松，等．电针治疗非酒精性脂肪性肝炎的临床观察．湖北中医杂志，2005，27(8)：9-11．
26．范建高．脂肪性肝病．北京：人民卫生出版社，2005，200．
27.Blechacz B, Stremmel W. NASH-nonalcoholic steatohepatitis. Z Gastroenterol. 2003 Jan; 41(1): 77-90.
28.Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21(1):3-16.
29.Lang ZW, Hu ZJ, Wang SK, et al. A clinicopathological study on nonalcoholic steatohepatitis. Zhonghua Gan Zang Bing Za Zhi. 2003 Feb; 11 (2):81-83.
30.Bahrami H, Daryani NE, MIRmomen S, et al. Clinical and histological features of nonalcoholic steatohepatitis in IRanian patients. BMC Gastroenterol. 2003 Oct 16;3(1):27.
31.Gramlich T, Kleiner DE, McCullough AJ, et al. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol. 2004 Feb;35(2):196-199.
32．赵亚飞．非酒精性脂肪性肝炎的发病机制研究进展．中国航天医药杂志，2003，5(2)：77．
33.Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003 Aug;38(2):536.
34.Day CP, James OF. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998;114:842-845.
35.Wanless IR, Shiota K .The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cIRrhosis. Semin Liver Dis. 2004 Feb;24(1):99-106.
36. Moreno Sanchez D. Pathogenesis of primary nonalcoholic fatty liver disease. Med Clin (Bare). 2005 May 7;124(17):668-877.
37. Chitturi S, Farrell GC. Etio-pathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001;21(1):27-41.
38. Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 575-594.
39. Basaranoglu M. Serum levels of triglyceride and Insulin resistance in patients with nonalcoholic steatohepatitis. Can J Gastroenterol. 2002 May;16(5):303-307.
40. Zamin i Jr, de Mattos AA, Zettler CG. Nonalcoholic steatohepatitis in nondiabetic obese patients. Can J Gastroenterol. 2002 Nov; 16(11):813-814.
41. Younossi ZM, Gramlich T, Matteoni CA, et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004 Jun;2(6):522.
42. Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and moblLization in the pathogenesis of Insulin resistance and type 2 diabetes. Endocr Rev 2002;23:201-229.
43. Duseja A, Murlidharan R, Bhansali A, et al. Assessment of Insulin resistance and effect of metformin in nonalcoholic steatohepatitis--a preliminary report, indian J Gastroenterol. 2004 Jan-Feb;23(1):12-15.
44. Lieber CS. CYP2E1: from ASH to NASH. Hepatol Res. 2004 Jan;28(1):1-11.
45. Prandota J. important role of prodromal vIRal infections responsible for inhibition of xenobiotic metabolizing enzymes in the pathomechanism of idiopathic Reye's syndrome, Stevens-Johnson syndrome, autoimmune hepatitis, and hepato-toxicity of the therapeutic doses of acetaminophen used in genetically predisposed persons. Am J Ther. 2002 Mar-Apr;9(2):149-156.
46. Day CP, James OF. Hepatic steatosis : innocent by stander or guILty party ? Hepatology, 1998 , 27 : 1463-1466.
47. Weltman MD, Farrell GC, Hall P, et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology. 1998 Jan;27(1):128-133.
48. Dai N, Zeng M, Li J. Correlation between hepatocyte cytochrome P450iiEl expression and oxidation, antioxidation in rat nonalcoholic steatosis model] Zhonghua Gan Zang Bing Za Zhi. 1999 Jun; 7(2): 104-106.
49. Gochee PA, Jonsson JR, Clouston AD, et al. Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen i, tumor necrosis factor-alpha and cytochrome P450 2E1. J Gastroenterol Hepatol. 2003 Apr;18(4):386-392.
50. Emery MG, Fisher JM, Chien JY, et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatol-ogy. 2003 Aug;38(2):428-435.
51. Chitturi, S, and Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis2001,21: 27-41.
52. Koruk M, Taysi S, Savas MC, et al. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Ann Clin Lab Sci. 2004 Win-ter;34(1):57-62.
53. Mehta K, Van Thiel DH, Shah N, et al. Nonalcoholic fatty liver disease: patho-genesis and the role of antioxidants. Nutr Rev. 2002 Sep; 60(9):289-293.
54. YANG, ZHUH, LiH, et al. Mitochondrial adaptations to obesity related oxidant stress[J]. Arch Bio-chem Biophys, 2000,378(2):259-268.
55. Prandota J. important role of prodromal vIRal infections responsible for inhibition of xenobiotic metabolizing enzymes in the pathomechanism of idiopathic Reye's syndrome, Stevens-Johnson syndrome, autoimmune hepatitis, and hepato-toxicity of the therapeutic doses of acetaminophen used in genetically predisposed persons. Am J Ther. 2002 Mar-Apr;9(2): 149-156.
56. Lieber CS. CYP2E1: from ASH to NASH. Hepatol Res. 2004 Jan;28(1):1-11.
57. Begriche K, igoudjIL A, Pessayre D, et al. Mitochondrial dysfunction in NASH: Causes, consequences and possible means to prevent it. Mitochondrion. 2006 Feb;6(1):1-38.
58. Videla LA, Rodrigo R, Araya J, et al. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med. 2004 Nov l;37(9):1499-1507.
59. Perez-Carreras M, Del Hoyo P, Martin MA, et al. Defective hepatic mitochondrial respIRatory chain in patients with nonalcoholic steatohepatitis. Hepatology. 2003 Oct;38(4):999-1007.
60. Robertson G, Leclercq i, Farrell GC. Nonalcoholic steatosis and steatohepatitis. ii. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol. 2001 Nov;281(5):G1135-1139.
61. Fromenty B, Robin MA, igoudjIL A, et al. The INS and outs of mitochondrial dysfunction in NASH. Diabetes Metab. 2004 Apr; 30(2): 121-138.
62. Herbert T , Anna M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl Med , 2000 , 343 : 1467-1476.
63. Marsano L, McClain CJ. Cytokines and NASH: a pILot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003 Aug;38(2):413-419.
64. wiggAT, Roberts iC, Dymock RB, et al. The role of mall.intestimal bacterial overgrowth and tumor necrosis factor-ain the pathogenesis of nonalcoholic stea-toepatitis[J].Gut,2001,48(2):206.
65. Crespo J, Cayon A, Fernandez-GIL P, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 2001 Dec;34(6):1158-1163.
66. Lieber CS, Leo MA, Mak KM, et al. Model of nonalcoholic steatohepatitis. Am J Clin Nutr. 2004 Mar;79(3):350-351.
67. Bahcecioglu iH, Yalniz M, Ataseven H, et al. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastro-enterology. 2005 Sep-Oct; 52(65):1549-1553.
68. Oz HS, im HJ, Chen TS, et al. Glutathione-enhancing agents protect agalNSt steatohepatitis in a dietary model. J Biochem Mol Toxicol. 2006;20(1):39-47.
69. RibeIRo PS, Cortez-Pinto H, Sola S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol. 2004 Sep;99(9):1708-1717.
70. Valenti L, Fracanzani AL, Dongiovanni P, et al. Tumor necrosis factor alpha promoter polymorphisms and Insulin resistance in nonalcoholic fatty liver disease. Gastroenterology. 2002 Feb;122(2):274-280.
71.Adams LA, Zein CO, Angulo P, et al. A piLot trial of pentoxifylline in nonalco- holic steatohepatitis. Am J Gastroenterol. 2004 Dec;99(12):2365-2368.
72.Hui JM, Hodge A, Farrell GC, et al. Beyond Insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004 Jul;40(1): 19-22.
73.Pessayre, D, Berson A, Fromenty B, et al. Mitochondria in steatohepatitis. Semin Liver Dis 2001,21: 57-69.
74.Magnusson C, Vaux DL. Signalling by CD95 and TNF receptors: not only life and death. immunol Cell Biol 1999;77:41-46
75．赵亚飞．非酒精性脂肪性肝炎的发病机制研究进展．中国航天医药杂志，2003，5(2)：77-78．
76.George D K,Goldwurm S,Macdonald G A,et al.Lncreased hepatic IRon concen- tration in nonalcoholic steatohepatitis is associated with increased fibro- sis.Gastroenterology, 1998; 114:311-318.
77.Turlin B,Mendler MN,MoIRand R,et al.Histologic features of the liver in Insulin resistance associated IRon overloasd [J].AmJ Cin pathol,2001,116(1):263-270.
78.AnghILei LJ,Esposito M,Fulcheri E,et al.IRon-ethanol synergism and pathologi- cal liver transformation.in Vivo, 1999; 13:13-20.
79.Younossi ZM,Gramlich T,Bacon BR,et al.Hepatic IRon and nonalcoholic fatty liver disease,Heptology, 1999;30:847-850.
80.ColliNS S Kuhn C M, PetroAE, et al. Role ofleptin in fat regulation. Nature, 1996, 25:380(6576), 677.
81.Zhang Y Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature, 1994; 372:425.
82.Halaas J L, Gajiwala K S, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science, 1995; 269:543
83.Pelley mounter M A, Cullen M J, Baker M B, et al. Effect of the obese gene producton body weight regulation in ob/ob mice. Science, 1995; 269:540.
84.Stphens T W,BasINSki M,Bristow P K, etal.The role of neropeptide Y in the an- tiobesity action of the obese gene product .Nature, 1995; 377:530.
85.Haluzik M, Fiedler J, Nedvidkova J, et al. Serum leptin levels in patients with hyperlipidemias. Nutrition 2000; 16(6):429.
86. Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory re- sponses.FASEBJ, 1998, 12:57.
87． 孙丽伟，陈芝芸，等．高脂饮食脂肪肝大鼠血清血清TNF-α、IL-6、Leptin的变化的变化．浙江中医学院学报．2004：3(28)41-42．
88. Tobe K Oguer T Tauka moto C et al. Relationship between serum leptin and fatty liver in Japanese male adolescent university students. AMJ Gastroenterology,1999, 94(11):3328
89. Nathens ABR,Biaar RWG,Watson TBi, et al. Thiol-mediated regulation of iCAM-1 expression in endotoxin-induced acute lung injury. Jimmu nol, 1998,160:2959-2966.
90. Arrigo AP. Gene expression and thiolredox state.Free Radic Biol Med,1999,27:936-994.
91. Beg AA, Finco T S, Nantermet P V, et al. Tumor necrosis factor and inter- leukin-1 lead to phosphorylation and loss of I κ B α : a mechanism for NF- κ B activation. Mol Cell Biol. 1993;13:3301-3310.
92. Baeuerle PA, Baltimore D. NF- κ B: ten years after. Cell. 1996;87:13-20.
93. Baldwin AS. The NF-κ B and I κ BproteINS: new discoveries and INSights. Annu Rev immunol. 1996; 14:649-681.
94. Tak PP, FIRestein GS.NF-κB: a key role in inflammatory disease. JClininvest, 2001, 107:7-11.
95. WhitesideST, israelA.IκBprotein: structure, functionandreg-ulation. SeminCancerBiol, 1997,8:75-82.
96. BowisA, O/NelL1LA.Oxidative stress and nuclea rfactor-kap-paB ac tivation .Biochem Pharmacol,2000,59:12-23.
97. Schenk H,Klein M,Erdbrugger W, et al. Distinct effect of thio redoxin and antioxidants on the activation of transcription factor NF-kappaB AP- 1.Proc Natl Acad Sci USA, 1994,91:1672-1676.
98. Sdk CK,Packer L.Antioxidant and redoxregulation of genetranscrip tion. FASEBJ, 1996, 10: 709-720.
99. Hutter D,Greene JJ. influence of the cellular redoxstate on NF-kappaB-regulated gene expression. J Cell Physiol,2000,141:901-909
100.RibeIRo PS, Cortez-Pinto H, Sola S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol. 2004 Sep; 99(9):1708-1717.
101．范建高徐正婕王国良，等．大鼠非酒精性脂肪性肝炎形成过程中血清内毒素含量的变化．中华肝脏病杂志，2003，11(2)：73-76．
102.Zhu Yijun,Kan Lixin,Qi Chao,et al.J Bio Chem,2000;275:13510
103.Ye JM, iglesias MA, Watson DG,Ellis B ,Wood L,Jensen PB,Sorensen RV, Larsen PJ,Cooney GJ, Wassermann K,KraegenEW.Am J Physio Endocrinol Me-tab, ,2003 ;284(3):E531-540.
104．芮莉莉，吕品，田润芝，等．PPAR γ及与胰岛素抵抗的研究进展．科学技术与工程，2004，4(6)：500-502．
105.Kon K, ikejima K, Tipoe GL, et al. Dietary saturated fatty acides reverse inflam-matory and fibrotic changes in rat liver despite continued ethanol administration. J Pharmacol Exp Ther, 2001,299:638-644.
106．赵彩彦，王建彬，邓卓军，等．大鼠肝组织核因子-kB活性变化与PPARr表达的关系．中华肝脏病杂志．2005，13(2)96-100．
107．历有名，夏维新．脂肪肝现代诊疗．江苏科学技术出版社．第1版．2003，1：2233
108．范建高，曾民德．脂肪性肝病．北京：人民卫生出版社，2005，202．
109.Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical re- view. Dig Dis Sci. 2005 Jan; 50(1): 171-180.
110.Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001; 21(1):3-16.
111.Brunt EM. Alcoholic and nonalcoholic steatohepatitis. Clin Liver Dis. 2002 May; 6(2): 399-420
112.Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003 Aug; 38(2): 536.
113．范建高．脂肪性肝病．北京：人民卫生出版社，2005，202-203．
114．钟岚，范建高，王国良，等．肥胖、高脂血症性脂肪性肝炎模型的建立．实验动物科学与管理，2000，17(2)：19．
115. Yang SQ, Lin HZ, Lane MD, et al. Obesity increase sensivity to endotoxin liver injury: implication for the pathigenesis of steatohepatitis. Proc Natl Acad Sci USA[J] 1997,94(60):2557-2562.
116．张玉峰，陈文慧．非酒精性脂肪肝动物模型造模方法的研究．中西疾结合肝病杂志，2002，12(2)：124．
117．钟岚，范建高．非酒精性脂肪肝动物模型．国外医学．消化系疾病分册，1999，19(3)：177．
118.Sax HC, Talamini MA, Bracken K, et al. Hepatic steatosin in parentel nutrition, failure of fatty infiLtration to correlate with abnormal semum hepatic enzyme levels. Surgery, 1986,100 (8):697
119．范建高 曾民德 李继强等．Bezafibrate对大鼠高脂血症和脂肪肝形成的影响．胃肠病学和肝病学杂志，1999，8(2)：100-102
120．刘红菊．从腧穴 经络 脏腑相关性看针灸治病之机理．辽宁中医杂志，2002，29(3)：3
121．王凤珍，杨钦河，王强，等．中医药治疗脂肪肝临床研究进展．安徽中医学院学报，2006，25(1)：53．
122．杨一明，靳瑞，张家维．针刺对高脂血症患者高密度脂蛋白亚组分和其他脂质含量的影响[J]．针灸学报，1992，(1)：7．
123．周杰芳，冼志红．针刺对高血脂病人的血脂及血液流变学影响的临床观察．广西中医药，1994；17(3)：39．
124．王玉琴，甄薇，李黎斌，等．针刺对高胆固醇血症家兔影响的研究．中国针灸，1994；14(2)：32．
125．黄为敏，黄坤厚，徐青燕，等．电针对内毒素休克大鼠肝脏的影响．组织化学观察．针刺研究，1995；20(3)：53．
126．解秸萍，李晓泓，李蔚，等．丰隆穴化痰作用及机制探讨．针灸临床杂志，2006，22(1)：1-2．
127．程井军，吴其恺，贺劲松等．电针治疗非酒精性脂肪性肝炎的临床观察．湖北中医杂志，2005，27(8)：11．
128．施茵，周珊玲．足三里穴对神经-内分泌-免疫网络的调节作用．江西中医学院学报，2003，15(2)：37．
129．许建阳，冯琼．针灸双向良性作用通过神径—内分泌-免疫网络系统实现的假 说．贵阳中医学院学报，1997，19(3)：6-7．
130．刘志诚，孙凤崛，孙志等．针刺对肥胖大鼠瘦素、胰岛素和神经肽Y含量的影响．中国中医基础医学杂志，2003，9(10)：40．
131．赵英侠，余安胜，严振国．针灸足三里对老年大鼠SOD活性影响的实验研究[J]．陕西中医，1996，17(8)：379．
132．查炜，尚明华，孙亦农．不同配穴针灸对荷瘤CTX化疗小鼠抗氧化系统的影响[J]．南京中医药大学学报，2002，17(5)：312． ’
133．施茵，周珊玲．足三里穴对神经-内分泌-免疫网络的调节作用．江西中医学院学报，2003，15(2)：38．
134．王少锦，康锁彬，李爱英，等．针刺影响下丘脑性肥胖大鼠脂代谢相关因素的分析．针刺研究，2005，30(2)：75．
135．胡卫东，杨浩明，郑高坪，等．针灸治疗非酒精性脂肪性肝炎临床观察．广州中医药大学学报，2006，23(1)：39-40．
136．赵亚飞．非酒精性脂肪性肝炎的发病机制研究进展．中国航天医药杂志，2003，5(2)：78．
137.Ramalho RM, Cortez-Pinto H, et al. Castro RE,Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur J Gastroenterol Hepatol. 2006 Jan;18(1):21-29.
1.Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003 Aug;38(2):536.
2.Farrel GC . Non-alcoholic sleatoheppatitis: What is it, and why is it important in the Aisa-pacfic region? J Gastroenterol Hepatol, 2003, 18:124-138.
3.Larson A .Non-alcoholic sleatoheppatitis Clinical Reasearch Net- work.hepatology.2003,57:244.
4.Clark JM, Diehl AM.Defining nonalocolic fatty liver disease:implications for epi- demiologic studies.Gastroent-erology,2003,124:248-250.
5.Zimmet PAlberti KG,Shaw J.Global and societalimplications of the diabetesepi- demic.Nature,2001,414:782
6.Augulo PNonalcoholic fatty liver diseases.N Engl J Med,2002,346:1221-1231.
7．范建高，徐正婕．美国非酒精性脂肪肝病的诊断与共识．肝脏．2003，8(1)：58
8．杨少军，郑昱，陈开兵．中医药治疗脂肪肝的现状分析．甘肃中医学院学报．2002，(2)：106-107
9.Nomura H, Kashiwagi S, Hayashi J, et al. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988;27: 142-149.
10.Tominaga K, Kurata JH, Chen YK, et al. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci 1995;40:2002-2009.
11.Shen L, Fan JG, Shao Y, et al. Prevalence of nonalcoholic fatty liver among ad- ministrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 2003;9:1106-1110.
12.Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for he- patic steatosis in northern Italy. Ann Intern Med 2000; 132:112-117.
13.Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonal- coholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-1292.
14.Silverman JF, Pories WJ, Caro JF. Liver pathology in diabetes mellims and mor- bid obesity. Clinical, pathological, and biochemical considerations. Pathol Annu 1989;24 Pt 1:275-302.
15．范竹萍非酒精性脂肪性肝炎研究进展[J]国外医学消化分册，1998，18：20
16.Chitturi S, Farrell GC.Etio-pathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001; 21 (1):27-41.
17．历有名，夏维新．脂肪肝现代诊疗．江苏科学技术出版社．第1版．2003，1：2233．
18．鲁超，邹宇宏，工建青，等．非酒精性脂肪性肝炎病因及发病机制研究进展．安徽医药，2006，10(2)：81．
19．鲁超，邹宇宏，工建青，等．非酒精性脂肪性肝炎病因及发病机制研究进展．安徽医药，2006，10(2)：82
20.Sanyal AJ, Campbell-Surgent C, Mirshahi F, et al.Nonalcoholic steatohepatitis association of insulin resistance and mitochondrial abnomali- ties. Casteroenterology 2001, 120(5): 1183-1192.
21.Peter St Rke, Christine Sempou,Isabelle leclerccg ,et al.Oxidative stress KLF6 and transfoming growth factor-?up-regulation differentiate nonalcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J Hepatology 2003,39(4): 538-546.
22.Isabelle leclercg Yves Horsman, Jean-Pierre Desager , Nathalie Del- zenno and Andre-Pierre Geubal Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the ab- sence of inflammation[ J]. J Hepatology 1998 28 410- 416.
23.Leclercq ZA, Farrel GC, Field J,et al. CYP Ⅱ E1 and CYP4A as catalysts of lipid peroxides in murine nonalcoholic steato. J clim invest 2000,105(8):1062.
24.Angulo P, Lindor KD. Insulin resistance and m itochondrial abnormalities in NASH:a cool look into a burning issued [J]. Gastroenterology 2001,1281-1285.
25.Paradis V, Perle muter G, Bonvoast F, etal.H igh glucose and hyperinsuline mia stimulate connective tissue growth factor expression a potential mechanism involved in progression to fiorosis in nonalcoholic steatohepatitis[J]. Hepatology 2001, 34(1):738-744.
26.Rashid J,Roberts EA. Nonalcoholic steatohepatitis in children, J Pediatr Gastro- enterel Nutr. 2002, 30(6): 48-53.
27.Marchesini G, Brizi M, Bianchi G, etal.Nonalcoholic fatty liver disease:a feature of the metabolic syndrome[J]. Diabetes 2001,50:1844-1850.
28.Herbert T, Anna M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N EnglMed, 2000, 343: 1467-1476.
29.Craig J, Shirish B, Ion D, et al . Cytokines in alcoholic liver disease.Semin Liver Dis, 1999, 19: 205-219.
30．顾长海，王宇明．肝功能衰蝎北京：人民卫生出版社，2002：51．
31．鲁超，邹宇宏，工建青，等．非酒精性脂肪性肝炎病因及发病机制研究进展．安徽医药，2006，10(2)：83．
32.Anna Mae Diehl Nonalcoholic steatosis and steatohepatitis Ⅳ, nonalcoholic fatty liver disease abnromalities in macrophage function and cytokines[J]. Am J Physiol Gastroinest liver physiol. 2002,282:1-5.
33.Grespo J, Hiktr MN Esqui M, et al. Gene expression of tumor necrosis factor alpha and TNF receptors P55 and P75 in nonalcoholic steatohepatitis patients [J]. Hepatology 2001, 34( 6):1185-1193.
34.Lauwerys BR, Garot N, Renauld JC, et a 1 Cytokine production and killer activity of NK/T-NK cells derived with combination of IL-12 andIL-18[J]. J Immunol,2000,165:1847-1853.
35.Chitturis S,Farell GC.Etiopathogenesis of nonalcoholic steatohepatitis[J]. Sem in Liver Dis, 2001,21: 27-41.
36. Halaas J L, Gajiwala K S, Maffei M, et al. Weight—reducing effects of the plasma protein encoded by the obese gene. Science, 1995; 269:543
37 .Pelley mounter M A, Cullen M J, Baker M B, et al. Effect of the obese gene producton body weight regulation in ob/ob mice. Science, 1995; 269:540.
38. Stphens T W,Basinski M,Bristow P K, etal.The role of neropeptide Y in the an-tiobesity action of the obese gene product .Nature, 1995; 377-530.
39.Anna Mae Diehl Nonalcoholic steatosis and steatohepatitis IV, nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines[J].Am J Physiol Gastroinest liver physio,2002,282:285.
40.Brian P mulhall,Janus P ONG,and Zo Bair M Younossi Nonalcoholic fatty liver disease:An overview[J] J Gastroenterology and hepatology,2002,17:1336-1343.
41.Tak PP,Firestein GS.NF-κB: a key role in inflammatory disease. JClinlnvest, 2001, 107:7-11.
42.WhitesideSTIsraelA.I. K Bprotein: structure, functionandreg-ulation. SeminCan-cerBiol, 1997,8:75-82.
43.BowisA,O/NeillLA.Oxidative stress and nuclea rfactor-kap-paB activation .Biochem Pharmacol,2000,59:12-23.
44.Sdk CK,Packer L.Aritioxidant and redoxregulation of genetranscription. FASEBJ, 1996,10: 709-720.
45.Ribeiro PS, Cortez-Pinto H, Sola S,et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients.Am J Gastroenterol. 2004 Sep;99(9):1708-1717.
46.Zhu Yijun,Kan Lixin,Qi Chao,et al.J Bio Chem,2000;275:13510.
47.Ye JM, Iglesias MA, Watson DG,Ellis B ,Wood L,Jensen PB,Sorensen RV,Larsen PJ,Cooney GJ, Wassermann K,KraegenEW.Am J Physio Endocrinol Me- tab, ,2003;284(3):531—540.
48.Kon K, Ikejima K, Tipoe GL, et al. Dietary saturated fatty acides reverse inflam- matory and fibrotic changes in rat liver despite continued ethanol administration. J Pharmacol Exp Ther, 2001,299:638-644.
49．赵彩彦，王建彬，邓卓军，等．大鼠肝组织核因子-kB活性变化与PPARr表达的关系．中华肝脏病杂志．2005，13(2)96-100．
50.Day CP, James OFW I Steatohepatitis: a tale of t wo hit s? [J] 1 Gast roen-terology, 1998, 114: 842.
51．钟岚，范建高．非酒精性脂肪性肝炎发病机制的实验研究．中华消化杂志，2001，21(8)：481-484．
52.Galdwel SH,Hespenbeide EE, Subacute liver failure in obese women.Gastroenterol 2002, 97: 2058-2062.
53.Younossi ZM,Gramlich T,Bacon BR,et al.Hepatic iron and nonalcoholic fatty liver disease,Heptology, 1999;30:847-850.
54．历有名，夏维新．脂肪肝现代诊疗．江苏科学技术出版社．第Ⅰ版．2003，1：2233．
55.Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004;53:750-755.
56.Adams LA, Sanderson S, Lindor KD, et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biop-sies. J Hepatol 2005;42:132-138.
57.Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in pa-tients with cryptogenic cirrhosis: a case-control study. Hepatology 2000;32:689-692.
58.Powell EE, Cooksley WG; Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatol-ogy 1990; 11:74-80.
59.Marrero JA, Fontana RJ, Su GL, et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36:1349-1354.
60.Charlton M, Kasparova P, Weston S, et al. Frequency of nonalcoholic steatohepa-titis as a cause of advanced liver disease. Liver Transpl 2001;7:608-614.
61.Bugianesi E, Manzini P, D′Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepa-tology 2004;39:179-187.
62.Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
63.Ipekci SH, Basaranoglu M, Sonsuz A. The fluctuation of serum levels of ami- notransferase in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2003;36:371.
64.Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999;94:1018-1022.
65.Chitturi S, Weltman M, Farrell GC, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002;36:142-149.
66.Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoim- mune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2004;99:1316-1320.
67.Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123:745-750.
68.Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003 ;37:1202-1219.
69.Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
70.Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnor- mal liver function tests in the absence of diagnostic serology. J Hepatol 2001;35:195-199.
71.Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989; 111:473-478.
72.Mendez P, Regev A, Molina E, et al. Sampling error and reliability of liver biopsy in patients with nonalcoholic fatty liver disease (NAFLD). Hepatology 2003;38(Suppl 1):673.
73．范建高，徐正婕非酒精性脂肪性肝炎—从发病机制谈治疗对策．现代医药卫生，2004，20(2)：75-76．
74．潘俊，陈岳祥，非酒精性脂肪性肝炎的治疗进展。现代医药卫生，2003年19(5)：544．
75．戴林 邓彬 李爱萍 等 非酒精性脂肪性肝炎发病机制的实验研究．临床肝病杂志，2004，20(5)：286．
1．王凤珍，杨钦河，王强，等．中医药治疗脂肪肝临床研究进展．安徽中医学院学报，2006，25(1)：53．
2．王伯祥．中医肝胆病学[M]．北京：中国医药科技出版社，1993．438-445．
3．蒋森．降脂益肝汤治疗脂肪肝的临床观察[J]．中医杂志，1989(4)：24．
4．宋福印，李禾花．中西医结合治疗脂肪肝45例[J]．陕西中医，1991(3)：103．
5．杨环．复肝降脂汤治疗慢性肝炎合并脂肪肝41例[J]．陕西中医，1991(9)：396．
6．伍昌伟．大黄蚱虫丸治疗肥胖性脂肪肝[J]．四川中医，1990(10)：32．
7．李书奎．降脂复肝汤治疗脂肪肝35例[J]．陕西中医，1990(5)：208．
8．杨建辉．林鹤和治疗脂肪肝的经验[J]．江西中医药，2000，31(3)：1-2
9．朱小晓．清肝健脾活血汤治疗脂肪肝56例[J]．陕西中医，2002，23(7)：586．
10．潘志敏，李玉花．脂肪肝的病机及治疗研析[J]．浙江中医杂志，2004(1)：8-9．
11．张亚兵，邓阿黎．降脂护肝汤治疗脂肪肝40例[J]．中西医结合肝病杂志，2002，12(5)：305-306．
12．季光，郑培永．中医药治疗脂肪肝的研究述评[J]．中医药学刊，2004，22(1)：87-88．
13．佘大德．脂肪肝的诊断与治疗[J]．新中医2004，31(2)：55-56．
14．吴沛田．补泻兼施在脂肪肝治疗中的应用[J]．中医杂志，2001，42(12)：719-720．
15．吴杰，马翠兰．抗脂肪肝方药研究概述[J]．国医论坛，2000，15(5)：55-56．
16．潘金友，张爽秋，姚祖颐，等疏肝化瘀为主治疗脂肪肝[J]．辽宁中医杂志，2001，28(3)：152．
17．朱耀群，陈军贤，林祖辉．辨证分型治疗脂肪肝52例疗效观察[J]．新中医，2001，33(11)：26-27．
18．谢敏卿，付丽蓉．脂肪肝的中医药治疗[J]．光明中医，1998，13(6)：18-19．
19．李富．中西医结合治疗高脂血症脂肪肝疗效观察[J]．实用中西医结合杂志，1994(2)：104．
20．程锐．脂肪肝[M]．上海科学普及出版社2002．234．
21．花根才．降脂化浊汤治疗脂肪肝30例[J]．上海中医药杂志，1995(11)：13．
22．李富，高世文．辨证治疗脂肪肝32例临床观察[J]．吉林中医药1995(3)：18．
23．杨佩兰，周荣根．破瘀化浊方治疗脂肪肝120例[J]．四川中医，2000，18(2)：30．
24．许丽清．降脂调肝汤治疗脂肪肝30例临床观察[J]．江苏中医，1996，17(12)：9．
25．侯留法．酒肝康汤治疗酒精性脂肪肝32例[J]．河南中医，1997，17(4)：225-226．
26．裴道灵．健脾疏肝法治疗脂肪肝42例小结[J]．湖南中医杂志，2000，16(3)：35-36．
27．谭剑霞，陶琼．清浊降脂汤治疗脂肪肝47例[J]．湖南中医杂志，2000，16(3)：35-36．
28．黄哲，田德禄．中医药防治酒精性肝病的研究进展[J]．北京中医药大学学报，2003(2)：72．
29．符朝岩，刁秀兰．降脂护肝冲剂治疗脂肪肝的临床研究[J]．辽宁中医杂志，2000(12)：551-552．
30．银醇云．辨证治疗脂肪肝58例临床观察[J]．湖南中医药导报2003，9(8)：20-21．
31．赵秀莉．中医辨治脂肪肝[J]．中国社区医师，2003，19(16)：13-14．
32吴益萍．辨证分型治疗脂肪肝87例[J]．实用中医药杂志，2000，16(7)：14．
33．谢绍武．脂肪肝病辨证分型用药探析[J]．中医药学刊，2003，19(5)：503．
34．裴道灵．周文卫主任治疗脂肪肝经验[J]．黑龙江中医药2000，(6)：39-40．
35．董汉良．脂肪肝的证治探析[J]．中国社区医师，2003，18(10)：35-36．
36．陈腾云，何敏．脂肪肝中医辨证论治体会[J]．中国误诊学杂志，2005，5(13)：2550-2551．
37．刘志诚，施小波，王沂争，等．针灸对单纯性肥胖病高密度脂蛋白胆固醇的影响[J]．针刺研究，1990，(3)：227．
38．王克勤．脂蛋白与动脉粥样硬化[M]．北京：人民卫生出版社，1995．348．
39．王玉堂，安华．针刺丰隆穴降血脂47例临床观察[J]．中国针灸，1990，(3)：21．
40．许玉民．针刺对缺血性中风血脂变化的观察．上海针灸杂志，1992，11(2)：13..
41．严洁，白净净，易受乡，等．针刺降血脂的疗效观察，中医杂志，1987，(8)：43．
42．李国鹏，任惠娟．针灸对女性更年期综合征高密度脂蛋白亚组分和其他脂质含量的影响[J]．南京中医学院学报，2002，18(11)：53-54．
43．戚丽宣，张仲徽，叶成鸪等．针刺治疗脑梗塞322例临床疗效及对血清高密度脂蛋白胆固醇、血液流变学、纤维蛋白元等指标观察，中国针灸，1988,10(3)：21．
44．陈瑞，梁凤霞，毛红蓉．针刺从脾论治高脂血症的临床研．中国中西医结合消化杂志，2003，11(3)：162．
45．焦新民，殷克敏，申卓彬，等．针刺降低血脂82例临床观察[J]．新中医，1985，(6)：32．
46．毛喜荣，王月冬，周逸平．针刺对冠心病患者血脂血糖的影响[J]．针灸临床杂志，1994，10(2)：26．
47．李忠仁，陆念祖，王肖曼，等．针刺治疗中风高脂血症临床观察[J]．中国针灸，1988，(4)：28．
48．常小荣，周国平，严洁，等．隔药饼灸对高脂血症患者血清HDL-C、LDL-C及其他脂质含量的影响．中国中医基础医学杂志，1999，5(2)：53．
49．蒋桂素．艾灸对血清三酸甘油酯及胆固醇的降脂作用观察[J]．上海针灸杂志，1987，(3)：11．
50．王凤玲，王晓红，王巧妹，等．灸神阙穴降脂抗衰老作用的研究[J]．中国针灸，1996，(9)：29．
51．高耀华，王竹行，陈新黔，等．降脂药灸治疗中老年高脂血症的临床研究．中国针灸，2000，20(2)：77
52．刘运珠．温针灸足三里对防治老年性疾病的临床观察[J]．中国针灸，1996，16(9)：7．
53．吴中朝，王玲玲，刘跃光，等．艾灸对老年人血液载脂蛋白研究[J]．中国针灸，1998，(5)：261．
54．陈晓萍．耳穴贴压法治疗高脂血症．上海中医药杂志，1991；(10)：27．
55．刘丕成．足三里穴位穿刺埋线对人体血清胆固醇的影响．新中医，1980；(5)：39
56．袁俏梅，史红辉．穴位埋线治疗高脂血症34例—附普拉固治疗30例对照[J]．浙江中医杂志，2002，37(9)：396．
57．唐胜修，唐萍．丰隆、足三里穴位注射治疗高脂血症的临床研究．广西医学，2000，22(6)：1402．
58．王华．丹参穴位注射治疗高脂血症40例临床分析[J]．中国针灸，1997，(8)：469-469．
59．张静．熊胆注射液穴位注射治疗高脂血症临床疗效观察[J]．针灸临床杂志，2001，17(3)：14-15．
60．刘晓辉．当归维生素B12混合穴位注射治疗高脂血症56例[J]时珍国医国药，2001，12(4)：360．
61．袁凌松，朱忠春，余明哲．针药结合对不同部位脑梗塞患者血清高、低密度脂蛋白的影响．上海中医药大学学报，2001，15(2)：28.
62．梁凤应．针灸对老年人高脂血症及高粘血症的影响．上海针灸杂志，1999，18(4)：10．
63．张向力，张丽萍，邹璐．针药并用治疗高脂血症50例临床观察．针灸临床杂志，2001，17(7)：2．
64．范冠杰，彭颖华．针药合用对非胰岛素依赖型糖尿病患者血脂影响的临床研究．中国针灸，1998，18(3)：139．
65．朱雅萍．电针治疗高脂血症60例[J]．吉林中医药，2001，(4)43-43．
66．韩舰华．不同时辰电针足三里对实验性高脂血症家兔的疗效观察．针刺研究，1998，(4)：278．
67．程井军，吴其恺，贺劲松，等．电针治疗非酒精性脂肪性肝炎的临床观察．湖北中医杂志，2005，27(8)：9-11．
68．广西南宁针灸研究所．针灸治疗心血管病高血脂51例临床疗效观察[J]．中国针灸，1982，(4)：10．
69．杨一明，靳瑞，张家维．针刺对高脂血症患者高密度脂蛋白亚组分和其他脂质含 量的影响[J]．针灸学报，1992，(1)：7．
70．刘志诚，孙凤岷，赵东红等．针刺对单纯性肥胖瘦素和胰岛素抵抗的影响研究．中医药学刊，2003，21(1)：40-42．
71．刘志诚，孙凤岷，朱苗花，等．针灸对非胰岛素依赖性糖尿病胰岛素抵抗的影响[J]．上海针灸杂志，2000，19(1)：5-7．
72．谌剑飞，马雅玲，丁萍，等．针刺对2型糖尿病患者免疫细胞因子、胰岛素敏感指数及血凝指标的影响[J]．中医杂志，2002，43(1)：30-32．
73．苗宇船，李瑞华．复方中药防治大鼠脂肪肝的实验研究[J]．山西中医学院学报，2003，4(2)：15-17．
74．何东仪，胡义扬．肝脂消方对ccl_4诱导大鼠肝脂肪变性时HDSase、ATPase的影响[J]．中国中西医结合消化杂志，2001，9(3)：133-135．
75．杨东娣，黄真炎．虎金丸对大鼠脂肪肝超微结构变化的影响[J]．中医药研究，2001，17(5)：43-44．
76．马晓燕，季雅玲．肝脂消煎剂对脂肪肝大鼠肝微粒体膜流动性及心肌黄酶、丙二醛的作用[J]．中国中西医结合消化杂志，2004，10(5)：284-286．
77．张卓，顾恪波．消脂护肝方对非酒精性脂肪肝大鼠脂质过氧化的影响[J]．中西医结合肝病杂志，2004，14(3)：155-157．
78夏瑾瑜，贾学平．肝脂康胶囊对非酒精性脂肪肝的防治作用[J]．中国中西医结合消化杂志，2004，12(1)：15-18．
79．官昭艳．双清片对大鼠实验性脂肪肝影响的实验研究[J]．中国中医药科技，2005，12(3)：156-157．
80．李石良，陈汉平，郑蕙田，等．针刺艾灸改善NIDDM大鼠脂代谢紊乱的作用机理[J]．针灸临床杂志，1995，11(2)：19．
81．杨丹红，许文波，江庆淇．穴位注射对高脂血症动物模型的降脂作用．针灸临床杂志，2000，16(1)：43．
82．王玉琴等．针刺对高胆固醇血症家兔影响的研究．中国针灸，1994；(2)：32．
83．程井军，吴其恺，贺劲松，等．电针对非酒精性脂肪性肝炎大鼠血清TNF-α及RI的影响．湖北中医学院学报，2005，7(3)：21．
84．桂金水，陈汉平，张时宜．艾灸抑制豚鼠肝脂肪变性的形态学观察[J]．解剖学杂志，1990，13(2)：110．
85．孙璇，李学武．天灸对大鼠脂肪肝治疗作用的实验研究[J]．北京中医药大学学报，2001，24(1)：48．
86．王凤珍，杨钦河，王强，等．中医药治疗脂肪肝临床研究进展．安徽中医学院学报，2006，25(1)：53．
2．范建高，曾民德，李继强，等．Bezafibrate对大鼠高脂血症和脂肪肝形成的影响．胃肠病学和肝病学杂志，1999，8(2)：100-102．
3．李忠仁．实验针灸学．北京：中国中医药出版社，2003：327-329．
4．孙璇，李学武．天灸对大鼠脂肪肝治疗作用的实验研究．北京中医药大学学报，2001，24(1)：48．
5．林文注．实验针灸学．上海：上海科学技术出版社，1994．
6．朱军，范建高，方继伟．东宝肝泰对大鼠高脂饮食脂肪性肝炎的预防作用．现 代医药卫生，2003，19(8)：951．
7.Blechacz B, Stremmel W. NASH - nonalcoholic steatohepatitis. Z Gastroenterol. 2003 Jan; 41(1):77-90.
8.DayC, James.Steatohepatitis: a tale of two " hits " . Gastroenterology,1998,114(4):842 845.
9．陆伦根，曾民德．改善胰导素抵抗在非酒精性脂肪性肝病防治中的作用．中华肝脏病杂志，2003，11(2)：113．
10．范建高，曾民德．脂肪性肝病．北京：人民卫生出版社，2005，336-337．
11.Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001; 21(1):3-16.
12.Bahrami H, Daryani NE, MIRmomen S, et al. Clinical and histological features of nonalcoholic steatohepatitis in IRanian patients. BMC Gastroenterol. 2003 Oct 16; 3(1):27.
13.Gramlich T, Kleiner DE, McCullough A J, et al. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol. 2004 Feb; 35(2):196-199.
14．范建高，曾民德．脂肪性肝病．北京：人民卫生出版社，2005，116．
15．胡坚文．中医对脂肪肝的认识和治疗探讨．湖北中医杂志，1998，20(3)：12
16．徐春军．肝、胆、胰疾病的针灸治疗．国外医学中医中药分册，1997，19(1)：51．
17．李洁，许佳年，张琴．针药结合治疗脂肪肝32例临床观察．湖南中医药导报，1999，6(5)：17-18．
1．范竹萍．非酒精性脂肪性肝炎研究进展[J]国外医学消化分册，1998，18：20
2.Chitturi S, Farrell GC.Etio-pathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis.2001,21 (1):27-41.
3．历有名，夏维新．脂肪肝现代诊疗．江苏科学技术出版社．第Ⅰ版．2003，1：2233．
4.Day CP, James OFW I Steatohepatitis: a tale of two hit s? [J] 1 Gast roen-terology, 1998, 114: 842.
5.Galdwell SH,hespenheide EE.Subacute Liver FaiLure in obese women[J].AM J Gastruenterology.2001,97(8):2058-2062.
6.Wanless IR., Shiota K .The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases:a four-step model including the role of lipid release and he-patic venular obstruction in the progression tocIRrhosis. Semin Liver Dis. 2004,24 ( 1 ) :99-106.
7.Bradbury MW, Berk PD.Lip id metabolism in hepatic steatosis. Clin Liver Dis. 2004,8(3):639-671.
8.Marchesini G, Bugianesi E, Foflani G, et al. Nonalcoholic fatty liver, steato-hepatitis, and the metabolic syndrome. Hepatology. 2003 Aug; 38(2):536.
9.Poniachik J, ManclLla C, Contreras J,et al. [Obesity: risk factor for steatohepati-tis and hepatic fibrosis] Rev Med ChlL. 2002 Jul;130(7):731-736.
10. Welt man MD, Farrell GC, Liddle C 1 Increased hepatocyte CYP2 El expression in a rat nutritional model of hepatic steatosis wit h inflammation [J] 1 Gastroen-terology, 1996, 111: 1645
11. Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and moblLization in the pathogenesis of Insulin resistance and type 2 diabetes. Endocr Rev 2002;23:201-229.
12. Duseja A, Murlidharan R, Bhansali A, et al. Assessment of Insulin resistance and effect of metformin in nonalcoholic steatohepatitis--a preliminary report. Indian J Gastroenterol. 2004 ,23(1):12-15.
13. Fromenty B, Robin MA, IgoudjIL A, et al. The INS and outs of mitochondrial dysfunction in NASH. Diabetes Metab 2004;30:121-138.
14. Chitturi S, Farrell GC.Etio-pathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis.2001; 21 (1) :27-41.
15. Mavrelis PG, Ammon HV, GleysteenJJ, et al . Hepatic free fattyacids in alcoholic liver disease and morbid obesity. Hepatology, 1983, 3: 226-231.
16. Day CP, James OF. Hepatic steatosis: Innocent bystander- or guILt ypart y? Hepatology, 1998, 27: 1463-1466.
17. Emery MQ Fisher JM, Chien JYCYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology. 2003 Aug;38(2):428-35.
18. Lieber CS.CYP2E1: from ASH to NASH. Hepatol Res. 2004 Jan;28(1): 1-11.
19. Cytochrome P-450 enzymes and oxidative stress.' Am J Physiol Gastrointest Liver Physiol. 2001Nov;281 (5) :1135-1139.
1. ChitturiS, Farrell GC.Etio-pathogenesis of nonalcoholicsteatohepatitis. Semin Liver Dis.2001; 21(1):27-41.
2. Chitturi S, and Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis, 2001[iSi]21: 29-40.
3. Mehta K, Van Thiel DH, Shah N, et al. Nonalcoholic fatty liver disease: patho- genesis and the role of antioxidants. Nutr Rev. 2002 Sep; 60(9):289-293.
4. YANG, ZHUH, LiH, et al. Mitochondrial adaptations to obesity related oxidant stress[J]. Arch Bio-chem Biophys, 2000,378(2):259 268.
5. Prandota J. important role of prodromal viRal infections responsible for inhibi- tion of xenobiotic metabolizing enzymes in the pathomechanism of idiopathic Reye's syndrome, Stevens-Johnson syndrome, autoimmune hepatitis, and hepato- toxicity of the therapeutic doses of acetaminophen used in genetically predis- posed persons. Am J Ther,2002 Mar-Apr;9(2): 149-156.
6. Gochee PA, Jonsson JR, Clouston AD, et al. Steatosis in chronic hepatitis C: as- sociation with increased messenger RNA expression of collagen i, tumor necrosis factor-alpha and cytochrome P450 2E1. J Gastroenterol Hepatol. 2003 Apr; 18(4):386-392.
7. George D K,Goldwurm S,Macdonald G A,et al.Lncreased hepatic IRon concen- tration in nonalcoholic steatohepatitis is associated with increased fibro- sis. Gastroenterology, 1998; 114:311 - 318.
8. Turlin B,Mendler MN,MoiRand R, et al.Histologic features of the liver in Insulin resistance associated IRon overloasd [J].AmJ Cin pathol, 2001,116(1):263-270.
9.AnghlLei LJ,Esposito M,Fulcheri E,et al.IRon-ethanol synergism and pathologi- cal liver transformation.in Vivo, 1999; 13:13-20
10.Younossi ZM,Gramlich T,Bacon BR,et al.Hepatic IRon and nonalcoholic fatty liver disease,Heptology, 1999;30:847-850
11.Videla LA, Rodrigo R, Araya J, et al. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med. 2004 Nov 1 ;37(9): 1499-507.
12.Perez-Carreras M, Del Hoyo P, Martin MA, et al. Defective hepatic mitochondrial respiRatory chain in patients with nonalcoholic steatohepatitis. Hepatology. 2003 Oct;38(4):999-1007.
13.Robertson G; Leclercq i, Farrell GC. Nonalcoholic steatosis and steatohepatitis, ii. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol. 2001 Nov; 281 (5): 1135-1139.
14.Fromenty B, Robin MA, igoudjlL A, et al. The INS and outs of mitochondrial dysfunction in NASH. Diabetes Metab. 2004 Apr;30(2): 121-138.
15.Muller T, Langner C, Fuchsbichler A, et al. immunohistochemical analysis of Mallory bodies in WILsonian and non-WILsonian hepatic copper toxicosis. Hepatology. 2004 Apr;39(4):963-969.
16.Leclercq iA, Farrell GC, Field J, Bell D, et al. CYP2E1 and CYP4A as micro- somal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J Clin invest, 2000,105:1067-1075.
17.Sanyal, AJ, Campbell-Sargent C, MIRshahi F, et al. Nonalcoholic steatohepatitis: association of Insulin resistance and mitochondrial abnormalities. Gastroenterol-ogy, 2001,120: 1183-1192.
18．王玉堂，安华．针刺丰隆穴降血脂47例临床观察[J]．中国针灸，1990，(3)：21．
19．许玉民．针刺对缺血性中风血脂变化的观察．上海针灸杂志，1992，11(2)：13．
20．伦新，荣莉．足三里、关元穴隔姜灸对老年人SOD、T细胞亚群的影响[J]．新中医，1999，6(6)：24．
21．孔立红，陈友梅，郭桂荣，等．针灸对糖尿病大鼠血清SOD及MDA的影响及其比较研究[J]．中国针灸，1998，17(4)：42-43．
22．刘庆忠，郑灏泳．针刺对小鼠CAT、GSH-PX活性的影响[J]．针灸临床杂志，2001，17(4)：51-52．
23．孙忠人，赵英，毕克滨，等．足三里抗衰老作用的实验研究[J]．针灸临床杂志，1996，12(2)：33．
1. Rouach H, Fataccioli V, GentlL M, et al.Effect of Chronic ethanol feeding on lipid peroxidation and protein oxidation i radiation to liver pathology. Hepatology, 1997, 25:35.
2. Fan JS, Zhuang H, Li YG, et al. Serotyping and genotyping of hepatitits B among HBsAg positive and negative hepatitis B patients in 8 cities of China. Zhonghua Weishengwuxue He Mianyixue Zazhi, 1998,18:88-91
3． 彭亚琴，彭利，徐松菊，等．活血化瘀、化痰利湿法对大鼠肥胖相关性脂肪肝的作用．华中医学杂志．2004，28(1)：21．
4. Herbert T, Anna M. Cytokines in alcoholic and nonalcoholic steato hepatitis. N EnglMed, 2000, 343: 1467.
5. Craig J, ShlRish B, ion D, et al . Cytokines in alcoholic liver disease.Semin LiverDis, 1999, 19: 2052-2219.
6． 顾长海，王宇明．肝功能衰蝎北京：人民卫生出版社，2002：51．
7. wiggat Roberts, Dymock RB,et al..The role of mall.intestimal bacterial over- growth and tumor necrosis factor- a in the pathogenesis of nonalcoholic steato- hepatitjs[J].Gut, 2001,48(2):206.
8. Day CRNASH-related Liver FaiLure:One hit too many?[J].Am J Gastroenterol-ogy,2001,97: 1872-1874.
9. RibelRo PS, Cortez-Pinto H, Sola S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and al- coholic steatohepatitis patients. Am J Gastroenterol. 2004 Sep;99(9): 1708-1717.
10. Pessayre D, Berson A, Fromenty B, et al. Mitochondria in steatohepatitis. Semin Liver Dis, 2001,21: 57-69,.
11. Magnusson C, Vaux DL. Signalling by CD95 and TNF receptors: not only life and death, immunol Cell Biol 1999;77:41-46.
1. Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic Insulin resistance in non-alcoholic fatty liver disease. J Biol Chem, 2004, 279:32345-32353
2. Kanauchi M. A new index of Insulin sensitivity obtained from the oral glucose tolerance test applicable to advanced type 2 diabetes. Diabetes Care, 2002,25:1891-1892
3． 陆伦根，曾民德．改善胰导素抵抗在非酒精性脂肪性肝病防治中的作用．中华肝脏病杂志，2003，11(2)：113．
4． 陈卫星，虞朝辉，厉有名，等．非酒精性脂肪肝与胰岛素抵抗及糖代谢异常的关系．中华肝脏病杂志，2000，8(2)：76-77．
5. LeroyP, DessolinS, VILlageois P, etal.JBiolChem, 1996, 271:2365-2368.
6. Kolaczyski J W, Nyce M R, Considine RV, et al.Diabetses, 1996, 45:699-701.
7. Lee K N, Jeong i C, Lee S J, et al. Regulation ofleptin gene expression- byInsulin and growth hormone in mouse adipocytes[J]. Exp Mol Med, 2001, 33:234 239.
8. Lee J W, Romsos DR. Leptin deficient mice commence hypersecreting Insulin in response to acetylcholine between 1 and 2 weeks of age[J]. Exp Biol Med(May wood), 2001, 226:906 911.
9. Timothy J, Scott Heller R, Colin AL, et al. Leptin suppression of Insulin secretion by the activation of ATP-sensitive K~+ channels in pancreatic-cells[J].Dia betes, 1997, 46:1087 1093.
10． 刘志诚，孙凤岷，等．针刺对肥胖大鼠瘦素水平和瘦素受体基因表达的作用．Chinese Acupuncture&Moxibustio．2003：7(23)412-414．
1. Fan JS, Zhuang H, Li YG, et al. Serotyping and genotyping ofhepatitits B among HBsAg positive and negative hepatitis B patients in 8 cities of China. Zhonghua Weishengwuxue He Mianyixue Zazhi, 1998,18:88-91
2． 范建高曾民德李继强等．Bezafibrate对大鼠高脂血症和脂肪肝形成的影响．胃肠病学和肝病学杂志，1999，8(2)：100-102．
3. Stuyver L, De Gendt S, Van Geyt C, et al. A new genotype of hepatitis B viRus: Complete genome and Phylogenetic relatedness. J BenvlRol,2000,81 (Pt 1):67-74.
4. Rouach H, Fataccioli V, GentIL M, et al.Effect of Chronic ethanol feeding on lipid peroxidation and protein oxidation radiation to liver pathology. Hepatology, 1997, 25:35.
5． 范建高，曾民德．脂肪肝．上海：上海医科大学出版社，2000．204．
6． 郭留芹，姜春萌，王朝晖．柴胡、丹参复方对非酒精性脂肪肝大鼠的干预．中国临床康复，2006，10(15)：117．
7. Han C, Demetris AJ, Michalopooulos G, et al. 85-kDa cPLA plays a critical role in PPAR-mediated gene transcription in human hepatoma cells. Am J Physiol Gastrointest Liver Physiol, 2002, 282:586-597.
8. Everett L, Galli A, Crabb D. The role of hepatic peroxisome proliferator-actived receptors in health and disease. Liver, 2000, 20:191-199.
9. Bradbury MW, Berk PD. Lipid metabolism in hepatic steatosis, lin Liver Dis, 2004,8:639-671.
10. Sung CK, She H, Xiong S, et al. Tumor necrosiss factor-alpha inhibits perox- isome proliferator-actived receptor gamma activity at a posttranslational level in hepatic stellate cells. Am J Physio Gastrointest Liver Physiol, 2004,286:722-729.
11． 赵彩彦，王建彬，邓卓军，等．大鼠肝组织核因子-kB活性变化与PPAr表达的关系．中华肝脏病杂志．2005，13(2)96-100．
1．李正全，庞佑清．中医肝胆病证学．人民卫生出版社．第一版．2003，2：320．
2．徐列明，胡义扬，曾民德．脂肪性肝病．北京：人民卫生出版社，2005，537．
3．范建高，曾民德．脂肪性肝病．北京：人民卫生出版社，2005，538-539．
4．骆传佳，何启会，蒋大春，等．辨证与辨病相结合治疗非酒精性脂肪性肝炎的临床观察．中西医结合肝病杂志，2004，14(5)：274．
5．范建高，徐正婕．美国非酒精性脂肪肝病的诊断与共识．肝脏．2003，8(1)：58．
6．北京中医医院编．关幼波临床经验选．人民卫生出版社，1979：98．
7．姚国科，乔爱萍．辨证治疗脂肪肝46例．中国医药学报，1995，10(6)：31．
8．杨建辉．林鹤和治脂肪肝的经验．江西中医药，2000，31(3)：1．
9．徐列明，胡义扬，曾民德．脂肪性肝病．北京：人民卫生出版社，2005，537-539
10．王凤珍，杨钦河，王强，等．中医药治疗脂肪肝临床研究进展．安徽中医学院学报，2006，25(1)：53．
11．杨一明，靳瑞，张家维．针刺对高脂血症患者高密度脂蛋白亚组分和其他脂质含量的影响[J]．针灸学报，1992，(1)：7．
12．周杰芳，冼志红．针刺对高血脂病人的血脂及血液流变学影响的临床观察．广西中医药，1994；17(3)：39．
13．王玉琴，甄薇，李黎斌，等．针刺对高胆固醇血症家兔影响的研究．中国针灸，1994；14(2)：32．
14．黄为敏，黄坤厚，徐青燕，等．电针对内毒素休克大鼠肝脏的影响)))组织化学观察．针刺研究，1995；20(3)：53．
15．王威，于红，朴顺福，等．电针足三里穴对酒精性脂肪肝大鼠模型的影响．中国针灸，2004，24(12)：857-858．
16．解秸萍，李晓泓，李蔚，等．丰隆穴化痰作用及机制探讨．针灸临床杂志，2006，22(1)：1-2．
17．解秸萍，李晓泓，张露芬，等．针刺不同穴位对高脂血症大鼠血脂影响的实验研究．北京中医药大学学报，2003，26(5)：83．
18．胡卫东，杨浩明，郑高坪，等．针灸治疗非酒精性脂肪性肝炎临床观察．广州中医药大学学报，2006，23(1)：39-40．
19．王玉堂，安华．针刺丰隆穴降血脂47例临床观察[J]．中国针灸，1990，(3)：21．
20．刘晓辉．当归维生素B12混合穴位注射治疗高脂血症56例[J]时珍国医国 药，2001，12(4)：360．
21．徐春军．肝、胆、胰疾病的针灸治疗．国外医学中医中药分册，1997，19(1)：51．
22．孙璇，李学武．天灸对大鼠脂肪肝治疗作用的实验研究．北京中医药大学学报，2001，24(1)：48-50．
23．程井军，吴其恺，贺劲松，等．电针治疗非酒精性脂肪性肝炎的临床观察．湖北．中医杂志，2005，27(8)：11．
24．陈邦国．针刺对青壮年脑动脉硬化病人血脂的影响．河南中医，1998，18(1)：36-37．
25．程井军，吴其恺，贺劲松，等．电针治疗非酒精性脂肪性肝炎的临床观察．湖北中医杂志，2005，27(8)：9-11．
26．范建高．脂肪性肝病．北京：人民卫生出版社，2005，200．
27.Blechacz B, Stremmel W. NASH-nonalcoholic steatohepatitis. Z Gastroenterol. 2003 Jan; 41(1): 77-90.
28.Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21(1):3-16.
29.Lang ZW, Hu ZJ, Wang SK, et al. A clinicopathological study on nonalcoholic steatohepatitis. Zhonghua Gan Zang Bing Za Zhi. 2003 Feb; 11 (2):81-83.
30.Bahrami H, Daryani NE, MIRmomen S, et al. Clinical and histological features of nonalcoholic steatohepatitis in IRanian patients. BMC Gastroenterol. 2003 Oct 16;3(1):27.
31.Gramlich T, Kleiner DE, McCullough AJ, et al. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol. 2004 Feb;35(2):196-199.
32．赵亚飞．非酒精性脂肪性肝炎的发病机制研究进展．中国航天医药杂志，2003，5(2)：77．
33.Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003 Aug;38(2):536.
34.Day CP, James OF. Steatohepatitis: A tale of two "hits"? Gastroenterology 1998;114:842-845.
35.Wanless IR, Shiota K .The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cIRrhosis. Semin Liver Dis. 2004 Feb;24(1):99-106.
36. Moreno Sanchez D. Pathogenesis of primary nonalcoholic fatty liver disease. Med Clin (Bare). 2005 May 7;124(17):668-877.
37. Chitturi S, Farrell GC. Etio-pathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001;21(1):27-41.
38. Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 575-594.
39. Basaranoglu M. Serum levels of triglyceride and Insulin resistance in patients with nonalcoholic steatohepatitis. Can J Gastroenterol. 2002 May;16(5):303-307.
40. Zamin i Jr, de Mattos AA, Zettler CG. Nonalcoholic steatohepatitis in nondiabetic obese patients. Can J Gastroenterol. 2002 Nov; 16(11):813-814.
41. Younossi ZM, Gramlich T, Matteoni CA, et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004 Jun;2(6):522.
42. Lewis GF, Carpentier A, Adeli K, et al. Disordered fat storage and moblLization in the pathogenesis of Insulin resistance and type 2 diabetes. Endocr Rev 2002;23:201-229.
43. Duseja A, Murlidharan R, Bhansali A, et al. Assessment of Insulin resistance and effect of metformin in nonalcoholic steatohepatitis--a preliminary report, indian J Gastroenterol. 2004 Jan-Feb;23(1):12-15.
44. Lieber CS. CYP2E1: from ASH to NASH. Hepatol Res. 2004 Jan;28(1):1-11.
45. Prandota J. important role of prodromal vIRal infections responsible for inhibition of xenobiotic metabolizing enzymes in the pathomechanism of idiopathic Reye's syndrome, Stevens-Johnson syndrome, autoimmune hepatitis, and hepato-toxicity of the therapeutic doses of acetaminophen used in genetically predisposed persons. Am J Ther. 2002 Mar-Apr;9(2):149-156.
46. Day CP, James OF. Hepatic steatosis : innocent by stander or guILty party ? Hepatology, 1998 , 27 : 1463-1466.
47. Weltman MD, Farrell GC, Hall P, et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology. 1998 Jan;27(1):128-133.
48. Dai N, Zeng M, Li J. Correlation between hepatocyte cytochrome P450iiEl expression and oxidation, antioxidation in rat nonalcoholic steatosis model] Zhonghua Gan Zang Bing Za Zhi. 1999 Jun; 7(2): 104-106.
49. Gochee PA, Jonsson JR, Clouston AD, et al. Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen i, tumor necrosis factor-alpha and cytochrome P450 2E1. J Gastroenterol Hepatol. 2003 Apr;18(4):386-392.
50. Emery MG, Fisher JM, Chien JY, et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatol-ogy. 2003 Aug;38(2):428-435.
51. Chitturi, S, and Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis2001,21: 27-41.
52. Koruk M, Taysi S, Savas MC, et al. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Ann Clin Lab Sci. 2004 Win-ter;34(1):57-62.
53. Mehta K, Van Thiel DH, Shah N, et al. Nonalcoholic fatty liver disease: patho-genesis and the role of antioxidants. Nutr Rev. 2002 Sep; 60(9):289-293.
54. YANG, ZHUH, LiH, et al. Mitochondrial adaptations to obesity related oxidant stress[J]. Arch Bio-chem Biophys, 2000,378(2):259-268.
55. Prandota J. important role of prodromal vIRal infections responsible for inhibition of xenobiotic metabolizing enzymes in the pathomechanism of idiopathic Reye's syndrome, Stevens-Johnson syndrome, autoimmune hepatitis, and hepato-toxicity of the therapeutic doses of acetaminophen used in genetically predisposed persons. Am J Ther. 2002 Mar-Apr;9(2): 149-156.
56. Lieber CS. CYP2E1: from ASH to NASH. Hepatol Res. 2004 Jan;28(1):1-11.
57. Begriche K, igoudjIL A, Pessayre D, et al. Mitochondrial dysfunction in NASH: Causes, consequences and possible means to prevent it. Mitochondrion. 2006 Feb;6(1):1-38.
58. Videla LA, Rodrigo R, Araya J, et al. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med. 2004 Nov l;37(9):1499-1507.
59. Perez-Carreras M, Del Hoyo P, Martin MA, et al. Defective hepatic mitochondrial respIRatory chain in patients with nonalcoholic steatohepatitis. Hepatology. 2003 Oct;38(4):999-1007.
60. Robertson G, Leclercq i, Farrell GC. Nonalcoholic steatosis and steatohepatitis. ii. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol. 2001 Nov;281(5):G1135-1139.
61. Fromenty B, Robin MA, igoudjIL A, et al. The INS and outs of mitochondrial dysfunction in NASH. Diabetes Metab. 2004 Apr; 30(2): 121-138.
62. Herbert T , Anna M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl Med , 2000 , 343 : 1467-1476.
63. Marsano L, McClain CJ. Cytokines and NASH: a pILot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003 Aug;38(2):413-419.
64. wiggAT, Roberts iC, Dymock RB, et al. The role of mall.intestimal bacterial overgrowth and tumor necrosis factor-ain the pathogenesis of nonalcoholic stea-toepatitis[J].Gut,2001,48(2):206.
65. Crespo J, Cayon A, Fernandez-GIL P, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 2001 Dec;34(6):1158-1163.
66. Lieber CS, Leo MA, Mak KM, et al. Model of nonalcoholic steatohepatitis. Am J Clin Nutr. 2004 Mar;79(3):350-351.
67. Bahcecioglu iH, Yalniz M, Ataseven H, et al. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastro-enterology. 2005 Sep-Oct; 52(65):1549-1553.
68. Oz HS, im HJ, Chen TS, et al. Glutathione-enhancing agents protect agalNSt steatohepatitis in a dietary model. J Biochem Mol Toxicol. 2006;20(1):39-47.
69. RibeIRo PS, Cortez-Pinto H, Sola S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol. 2004 Sep;99(9):1708-1717.
70. Valenti L, Fracanzani AL, Dongiovanni P, et al. Tumor necrosis factor alpha promoter polymorphisms and Insulin resistance in nonalcoholic fatty liver disease. Gastroenterology. 2002 Feb;122(2):274-280.
71.Adams LA, Zein CO, Angulo P, et al. A piLot trial of pentoxifylline in nonalco- holic steatohepatitis. Am J Gastroenterol. 2004 Dec;99(12):2365-2368.
72.Hui JM, Hodge A, Farrell GC, et al. Beyond Insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004 Jul;40(1): 19-22.
73.Pessayre, D, Berson A, Fromenty B, et al. Mitochondria in steatohepatitis. Semin Liver Dis 2001,21: 57-69.
74.Magnusson C, Vaux DL. Signalling by CD95 and TNF receptors: not only life and death. immunol Cell Biol 1999;77:41-46
75．赵亚飞．非酒精性脂肪性肝炎的发病机制研究进展．中国航天医药杂志，2003，5(2)：77-78．
76.George D K,Goldwurm S,Macdonald G A,et al.Lncreased hepatic IRon concen- tration in nonalcoholic steatohepatitis is associated with increased fibro- sis.Gastroenterology, 1998; 114:311-318.
77.Turlin B,Mendler MN,MoIRand R,et al.Histologic features of the liver in Insulin resistance associated IRon overloasd [J].AmJ Cin pathol,2001,116(1):263-270.
78.AnghILei LJ,Esposito M,Fulcheri E,et al.IRon-ethanol synergism and pathologi- cal liver transformation.in Vivo, 1999; 13:13-20.
79.Younossi ZM,Gramlich T,Bacon BR,et al.Hepatic IRon and nonalcoholic fatty liver disease,Heptology, 1999;30:847-850.
80.ColliNS S Kuhn C M, PetroAE, et al. Role ofleptin in fat regulation. Nature, 1996, 25:380(6576), 677.
81.Zhang Y Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature, 1994; 372:425.
82.Halaas J L, Gajiwala K S, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science, 1995; 269:543
83.Pelley mounter M A, Cullen M J, Baker M B, et al. Effect of the obese gene producton body weight regulation in ob/ob mice. Science, 1995; 269:540.
84.Stphens T W,BasINSki M,Bristow P K, etal.The role of neropeptide Y in the an- tiobesity action of the obese gene product .Nature, 1995; 377:530.
85.Haluzik M, Fiedler J, Nedvidkova J, et al. Serum leptin levels in patients with hyperlipidemias. Nutrition 2000; 16(6):429.
86. Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory re- sponses.FASEBJ, 1998, 12:57.
87． 孙丽伟，陈芝芸，等．高脂饮食脂肪肝大鼠血清血清TNF-α、IL-6、Leptin的变化的变化．浙江中医学院学报．2004：3(28)41-42．
88. Tobe K Oguer T Tauka moto C et al. Relationship between serum leptin and fatty liver in Japanese male adolescent university students. AMJ Gastroenterology,1999, 94(11):3328
89. Nathens ABR,Biaar RWG,Watson TBi, et al. Thiol-mediated regulation of iCAM-1 expression in endotoxin-induced acute lung injury. Jimmu nol, 1998,160:2959-2966.
90. Arrigo AP. Gene expression and thiolredox state.Free Radic Biol Med,1999,27:936-994.
91. Beg AA, Finco T S, Nantermet P V, et al. Tumor necrosis factor and inter- leukin-1 lead to phosphorylation and loss of I κ B α : a mechanism for NF- κ B activation. Mol Cell Biol. 1993;13:3301-3310.
92. Baeuerle PA, Baltimore D. NF- κ B: ten years after. Cell. 1996;87:13-20.
93. Baldwin AS. The NF-κ B and I κ BproteINS: new discoveries and INSights. Annu Rev immunol. 1996; 14:649-681.
94. Tak PP, FIRestein GS.NF-κB: a key role in inflammatory disease. JClininvest, 2001, 107:7-11.
95. WhitesideST, israelA.IκBprotein: structure, functionandreg-ulation. SeminCancerBiol, 1997,8:75-82.
96. BowisA, O/NelL1LA.Oxidative stress and nuclea rfactor-kap-paB ac tivation .Biochem Pharmacol,2000,59:12-23.
97. Schenk H,Klein M,Erdbrugger W, et al. Distinct effect of thio redoxin and antioxidants on the activation of transcription factor NF-kappaB AP- 1.Proc Natl Acad Sci USA, 1994,91:1672-1676.
98. Sdk CK,Packer L.Antioxidant and redoxregulation of genetranscrip tion. FASEBJ, 1996, 10: 709-720.
99. Hutter D,Greene JJ. influence of the cellular redoxstate on NF-kappaB-regulated gene expression. J Cell Physiol,2000,141:901-909
100.RibeIRo PS, Cortez-Pinto H, Sola S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol. 2004 Sep; 99(9):1708-1717.
101．范建高徐正婕王国良，等．大鼠非酒精性脂肪性肝炎形成过程中血清内毒素含量的变化．中华肝脏病杂志，2003，11(2)：73-76．
102.Zhu Yijun,Kan Lixin,Qi Chao,et al.J Bio Chem,2000;275:13510
103.Ye JM, iglesias MA, Watson DG,Ellis B ,Wood L,Jensen PB,Sorensen RV, Larsen PJ,Cooney GJ, Wassermann K,KraegenEW.Am J Physio Endocrinol Me-tab, ,2003 ;284(3):E531-540.
104．芮莉莉，吕品，田润芝，等．PPAR γ及与胰岛素抵抗的研究进展．科学技术与工程，2004，4(6)：500-502．
105.Kon K, ikejima K, Tipoe GL, et al. Dietary saturated fatty acides reverse inflam-matory and fibrotic changes in rat liver despite continued ethanol administration. J Pharmacol Exp Ther, 2001,299:638-644.
106．赵彩彦，王建彬，邓卓军，等．大鼠肝组织核因子-kB活性变化与PPARr表达的关系．中华肝脏病杂志．2005，13(2)96-100．
107．历有名，夏维新．脂肪肝现代诊疗．江苏科学技术出版社．第1版．2003，1：2233
108．范建高，曾民德．脂肪性肝病．北京：人民卫生出版社，2005，202．
109.Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical re- view. Dig Dis Sci. 2005 Jan; 50(1): 171-180.
110.Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001; 21(1):3-16.
111.Brunt EM. Alcoholic and nonalcoholic steatohepatitis. Clin Liver Dis. 2002 May; 6(2): 399-420
112.Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003 Aug; 38(2): 536.
113．范建高．脂肪性肝病．北京：人民卫生出版社，2005，202-203．
114．钟岚，范建高，王国良，等．肥胖、高脂血症性脂肪性肝炎模型的建立．实验动物科学与管理，2000，17(2)：19．
115. Yang SQ, Lin HZ, Lane MD, et al. Obesity increase sensivity to endotoxin liver injury: implication for the pathigenesis of steatohepatitis. Proc Natl Acad Sci USA[J] 1997,94(60):2557-2562.
116．张玉峰，陈文慧．非酒精性脂肪肝动物模型造模方法的研究．中西疾结合肝病杂志，2002，12(2)：124．
117．钟岚，范建高．非酒精性脂肪肝动物模型．国外医学．消化系疾病分册，1999，19(3)：177．
118.Sax HC, Talamini MA, Bracken K, et al. Hepatic steatosin in parentel nutrition, failure of fatty infiLtration to correlate with abnormal semum hepatic enzyme levels. Surgery, 1986,100 (8):697
119．范建高 曾民德 李继强等．Bezafibrate对大鼠高脂血症和脂肪肝形成的影响．胃肠病学和肝病学杂志，1999，8(2)：100-102
120．刘红菊．从腧穴 经络 脏腑相关性看针灸治病之机理．辽宁中医杂志，2002，29(3)：3
121．王凤珍，杨钦河，王强，等．中医药治疗脂肪肝临床研究进展．安徽中医学院学报，2006，25(1)：53．
122．杨一明，靳瑞，张家维．针刺对高脂血症患者高密度脂蛋白亚组分和其他脂质含量的影响[J]．针灸学报，1992，(1)：7．
123．周杰芳，冼志红．针刺对高血脂病人的血脂及血液流变学影响的临床观察．广西中医药，1994；17(3)：39．
124．王玉琴，甄薇，李黎斌，等．针刺对高胆固醇血症家兔影响的研究．中国针灸，1994；14(2)：32．
125．黄为敏，黄坤厚，徐青燕，等．电针对内毒素休克大鼠肝脏的影响．组织化学观察．针刺研究，1995；20(3)：53．
126．解秸萍，李晓泓，李蔚，等．丰隆穴化痰作用及机制探讨．针灸临床杂志，2006，22(1)：1-2．
127．程井军，吴其恺，贺劲松等．电针治疗非酒精性脂肪性肝炎的临床观察．湖北中医杂志，2005，27(8)：11．
128．施茵，周珊玲．足三里穴对神经-内分泌-免疫网络的调节作用．江西中医学院学报，2003，15(2)：37．
129．许建阳，冯琼．针灸双向良性作用通过神径—内分泌-免疫网络系统实现的假 说．贵阳中医学院学报，1997，19(3)：6-7．
130．刘志诚，孙凤崛，孙志等．针刺对肥胖大鼠瘦素、胰岛素和神经肽Y含量的影响．中国中医基础医学杂志，2003，9(10)：40．
131．赵英侠，余安胜，严振国．针灸足三里对老年大鼠SOD活性影响的实验研究[J]．陕西中医，1996，17(8)：379．
132．查炜，尚明华，孙亦农．不同配穴针灸对荷瘤CTX化疗小鼠抗氧化系统的影响[J]．南京中医药大学学报，2002，17(5)：312． ’
133．施茵，周珊玲．足三里穴对神经-内分泌-免疫网络的调节作用．江西中医学院学报，2003，15(2)：38．
134．王少锦，康锁彬，李爱英，等．针刺影响下丘脑性肥胖大鼠脂代谢相关因素的分析．针刺研究，2005，30(2)：75．
135．胡卫东，杨浩明，郑高坪，等．针灸治疗非酒精性脂肪性肝炎临床观察．广州中医药大学学报，2006，23(1)：39-40．
136．赵亚飞．非酒精性脂肪性肝炎的发病机制研究进展．中国航天医药杂志，2003，5(2)：78．
137.Ramalho RM, Cortez-Pinto H, et al. Castro RE,Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis. Eur J Gastroenterol Hepatol. 2006 Jan;18(1):21-29.
1.Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003 Aug;38(2):536.
2.Farrel GC . Non-alcoholic sleatoheppatitis: What is it, and why is it important in the Aisa-pacfic region? J Gastroenterol Hepatol, 2003, 18:124-138.
3.Larson A .Non-alcoholic sleatoheppatitis Clinical Reasearch Net- work.hepatology.2003,57:244.
4.Clark JM, Diehl AM.Defining nonalocolic fatty liver disease:implications for epi- demiologic studies.Gastroent-erology,2003,124:248-250.
5.Zimmet PAlberti KG,Shaw J.Global and societalimplications of the diabetesepi- demic.Nature,2001,414:782
6.Augulo PNonalcoholic fatty liver diseases.N Engl J Med,2002,346:1221-1231.
7．范建高，徐正婕．美国非酒精性脂肪肝病的诊断与共识．肝脏．2003，8(1)：58
8．杨少军，郑昱，陈开兵．中医药治疗脂肪肝的现状分析．甘肃中医学院学报．2002，(2)：106-107
9.Nomura H, Kashiwagi S, Hayashi J, et al. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988;27: 142-149.
10.Tominaga K, Kurata JH, Chen YK, et al. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci 1995;40:2002-2009.
11.Shen L, Fan JG, Shao Y, et al. Prevalence of nonalcoholic fatty liver among ad- ministrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 2003;9:1106-1110.
12.Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for he- patic steatosis in northern Italy. Ann Intern Med 2000; 132:112-117.
13.Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonal- coholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-1292.
14.Silverman JF, Pories WJ, Caro JF. Liver pathology in diabetes mellims and mor- bid obesity. Clinical, pathological, and biochemical considerations. Pathol Annu 1989;24 Pt 1:275-302.
15．范竹萍非酒精性脂肪性肝炎研究进展[J]国外医学消化分册，1998，18：20
16.Chitturi S, Farrell GC.Etio-pathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001; 21 (1):27-41.
17．历有名，夏维新．脂肪肝现代诊疗．江苏科学技术出版社．第1版．2003，1：2233．
18．鲁超，邹宇宏，工建青，等．非酒精性脂肪性肝炎病因及发病机制研究进展．安徽医药，2006，10(2)：81．
19．鲁超，邹宇宏，工建青，等．非酒精性脂肪性肝炎病因及发病机制研究进展．安徽医药，2006，10(2)：82
20.Sanyal AJ, Campbell-Surgent C, Mirshahi F, et al.Nonalcoholic steatohepatitis association of insulin resistance and mitochondrial abnomali- ties. Casteroenterology 2001, 120(5): 1183-1192.
21.Peter St Rke, Christine Sempou,Isabelle leclerccg ,et al.Oxidative stress KLF6 and transfoming growth factor-?up-regulation differentiate nonalcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J Hepatology 2003,39(4): 538-546.
22.Isabelle leclercg Yves Horsman, Jean-Pierre Desager , Nathalie Del- zenno and Andre-Pierre Geubal Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the ab- sence of inflammation[ J]. J Hepatology 1998 28 410- 416.
23.Leclercq ZA, Farrel GC, Field J,et al. CYP Ⅱ E1 and CYP4A as catalysts of lipid peroxides in murine nonalcoholic steato. J clim invest 2000,105(8):1062.
24.Angulo P, Lindor KD. Insulin resistance and m itochondrial abnormalities in NASH:a cool look into a burning issued [J]. Gastroenterology 2001,1281-1285.
25.Paradis V, Perle muter G, Bonvoast F, etal.H igh glucose and hyperinsuline mia stimulate connective tissue growth factor expression a potential mechanism involved in progression to fiorosis in nonalcoholic steatohepatitis[J]. Hepatology 2001, 34(1):738-744.
26.Rashid J,Roberts EA. Nonalcoholic steatohepatitis in children, J Pediatr Gastro- enterel Nutr. 2002, 30(6): 48-53.
27.Marchesini G, Brizi M, Bianchi G, etal.Nonalcoholic fatty liver disease:a feature of the metabolic syndrome[J]. Diabetes 2001,50:1844-1850.
28.Herbert T, Anna M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N EnglMed, 2000, 343: 1467-1476.
29.Craig J, Shirish B, Ion D, et al . Cytokines in alcoholic liver disease.Semin Liver Dis, 1999, 19: 205-219.
30．顾长海，王宇明．肝功能衰蝎北京：人民卫生出版社，2002：51．
31．鲁超，邹宇宏，工建青，等．非酒精性脂肪性肝炎病因及发病机制研究进展．安徽医药，2006，10(2)：83．
32.Anna Mae Diehl Nonalcoholic steatosis and steatohepatitis Ⅳ, nonalcoholic fatty liver disease abnromalities in macrophage function and cytokines[J]. Am J Physiol Gastroinest liver physiol. 2002,282:1-5.
33.Grespo J, Hiktr MN Esqui M, et al. Gene expression of tumor necrosis factor alpha and TNF receptors P55 and P75 in nonalcoholic steatohepatitis patients [J]. Hepatology 2001, 34( 6):1185-1193.
34.Lauwerys BR, Garot N, Renauld JC, et a 1 Cytokine production and killer activity of NK/T-NK cells derived with combination of IL-12 andIL-18[J]. J Immunol,2000,165:1847-1853.
35.Chitturis S,Farell GC.Etiopathogenesis of nonalcoholic steatohepatitis[J]. Sem in Liver Dis, 2001,21: 27-41.
36. Halaas J L, Gajiwala K S, Maffei M, et al. Weight—reducing effects of the plasma protein encoded by the obese gene. Science, 1995; 269:543
37 .Pelley mounter M A, Cullen M J, Baker M B, et al. Effect of the obese gene producton body weight regulation in ob/ob mice. Science, 1995; 269:540.
38. Stphens T W,Basinski M,Bristow P K, etal.The role of neropeptide Y in the an-tiobesity action of the obese gene product .Nature, 1995; 377-530.
39.Anna Mae Diehl Nonalcoholic steatosis and steatohepatitis IV, nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines[J].Am J Physiol Gastroinest liver physio,2002,282:285.
40.Brian P mulhall,Janus P ONG,and Zo Bair M Younossi Nonalcoholic fatty liver disease:An overview[J] J Gastroenterology and hepatology,2002,17:1336-1343.
41.Tak PP,Firestein GS.NF-κB: a key role in inflammatory disease. JClinlnvest, 2001, 107:7-11.
42.WhitesideSTIsraelA.I. K Bprotein: structure, functionandreg-ulation. SeminCan-cerBiol, 1997,8:75-82.
43.BowisA,O/NeillLA.Oxidative stress and nuclea rfactor-kap-paB activation .Biochem Pharmacol,2000,59:12-23.
44.Sdk CK,Packer L.Aritioxidant and redoxregulation of genetranscription. FASEBJ, 1996,10: 709-720.
45.Ribeiro PS, Cortez-Pinto H, Sola S,et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients.Am J Gastroenterol. 2004 Sep;99(9):1708-1717.
46.Zhu Yijun,Kan Lixin,Qi Chao,et al.J Bio Chem,2000;275:13510.
47.Ye JM, Iglesias MA, Watson DG,Ellis B ,Wood L,Jensen PB,Sorensen RV,Larsen PJ,Cooney GJ, Wassermann K,KraegenEW.Am J Physio Endocrinol Me- tab, ,2003;284(3):531—540.
48.Kon K, Ikejima K, Tipoe GL, et al. Dietary saturated fatty acides reverse inflam- matory and fibrotic changes in rat liver despite continued ethanol administration. J Pharmacol Exp Ther, 2001,299:638-644.
49．赵彩彦，王建彬，邓卓军，等．大鼠肝组织核因子-kB活性变化与PPARr表达的关系．中华肝脏病杂志．2005，13(2)96-100．
50.Day CP, James OFW I Steatohepatitis: a tale of t wo hit s? [J] 1 Gast roen-terology, 1998, 114: 842.
51．钟岚，范建高．非酒精性脂肪性肝炎发病机制的实验研究．中华消化杂志，2001，21(8)：481-484．
52.Galdwel SH,Hespenbeide EE, Subacute liver failure in obese women.Gastroenterol 2002, 97: 2058-2062.
53.Younossi ZM,Gramlich T,Bacon BR,et al.Hepatic iron and nonalcoholic fatty liver disease,Heptology, 1999;30:847-850.
54．历有名，夏维新．脂肪肝现代诊疗．江苏科学技术出版社．第Ⅰ版．2003，1：2233．
55.Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004;53:750-755.
56.Adams LA, Sanderson S, Lindor KD, et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biop-sies. J Hepatol 2005;42:132-138.
57.Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in pa-tients with cryptogenic cirrhosis: a case-control study. Hepatology 2000;32:689-692.
58.Powell EE, Cooksley WG; Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatol-ogy 1990; 11:74-80.
59.Marrero JA, Fontana RJ, Su GL, et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36:1349-1354.
60.Charlton M, Kasparova P, Weston S, et al. Frequency of nonalcoholic steatohepa-titis as a cause of advanced liver disease. Liver Transpl 2001;7:608-614.
61.Bugianesi E, Manzini P, D′Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepa-tology 2004;39:179-187.
62.Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
63.Ipekci SH, Basaranoglu M, Sonsuz A. The fluctuation of serum levels of ami- notransferase in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2003;36:371.
64.Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999;94:1018-1022.
65.Chitturi S, Weltman M, Farrell GC, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002;36:142-149.
66.Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoim- mune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2004;99:1316-1320.
67.Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123:745-750.
68.Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003 ;37:1202-1219.
69.Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
70.Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnor- mal liver function tests in the absence of diagnostic serology. J Hepatol 2001;35:195-199.
71.Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989; 111:473-478.
72.Mendez P, Regev A, Molina E, et al. Sampling error and reliability of liver biopsy in patients with nonalcoholic fatty liver disease (NAFLD). Hepatology 2003;38(Suppl 1):673.
73．范建高，徐正婕非酒精性脂肪性肝炎—从发病机制谈治疗对策．现代医药卫生，2004，20(2)：75-76．
74．潘俊，陈岳祥，非酒精性脂肪性肝炎的治疗进展。现代医药卫生，2003年19(5)：544．
75．戴林 邓彬 李爱萍 等 非酒精性脂肪性肝炎发病机制的实验研究．临床肝病杂志，2004，20(5)：286．
1．王凤珍，杨钦河，王强，等．中医药治疗脂肪肝临床研究进展．安徽中医学院学报，2006，25(1)：53．
2．王伯祥．中医肝胆病学[M]．北京：中国医药科技出版社，1993．438-445．
3．蒋森．降脂益肝汤治疗脂肪肝的临床观察[J]．中医杂志，1989(4)：24．
4．宋福印，李禾花．中西医结合治疗脂肪肝45例[J]．陕西中医，1991(3)：103．
5．杨环．复肝降脂汤治疗慢性肝炎合并脂肪肝41例[J]．陕西中医，1991(9)：396．
6．伍昌伟．大黄蚱虫丸治疗肥胖性脂肪肝[J]．四川中医，1990(10)：32．
7．李书奎．降脂复肝汤治疗脂肪肝35例[J]．陕西中医，1990(5)：208．
8．杨建辉．林鹤和治疗脂肪肝的经验[J]．江西中医药，2000，31(3)：1-2
9．朱小晓．清肝健脾活血汤治疗脂肪肝56例[J]．陕西中医，2002，23(7)：586．
10．潘志敏，李玉花．脂肪肝的病机及治疗研析[J]．浙江中医杂志，2004(1)：8-9．
11．张亚兵，邓阿黎．降脂护肝汤治疗脂肪肝40例[J]．中西医结合肝病杂志，2002，12(5)：305-306．
12．季光，郑培永．中医药治疗脂肪肝的研究述评[J]．中医药学刊，2004，22(1)：87-88．
13．佘大德．脂肪肝的诊断与治疗[J]．新中医2004，31(2)：55-56．
14．吴沛田．补泻兼施在脂肪肝治疗中的应用[J]．中医杂志，2001，42(12)：719-720．
15．吴杰，马翠兰．抗脂肪肝方药研究概述[J]．国医论坛，2000，15(5)：55-56．
16．潘金友，张爽秋，姚祖颐，等疏肝化瘀为主治疗脂肪肝[J]．辽宁中医杂志，2001，28(3)：152．
17．朱耀群，陈军贤，林祖辉．辨证分型治疗脂肪肝52例疗效观察[J]．新中医，2001，33(11)：26-27．
18．谢敏卿，付丽蓉．脂肪肝的中医药治疗[J]．光明中医，1998，13(6)：18-19．
19．李富．中西医结合治疗高脂血症脂肪肝疗效观察[J]．实用中西医结合杂志，1994(2)：104．
20．程锐．脂肪肝[M]．上海科学普及出版社2002．234．
21．花根才．降脂化浊汤治疗脂肪肝30例[J]．上海中医药杂志，1995(11)：13．
22．李富，高世文．辨证治疗脂肪肝32例临床观察[J]．吉林中医药1995(3)：18．
23．杨佩兰，周荣根．破瘀化浊方治疗脂肪肝120例[J]．四川中医，2000，18(2)：30．
24．许丽清．降脂调肝汤治疗脂肪肝30例临床观察[J]．江苏中医，1996，17(12)：9．
25．侯留法．酒肝康汤治疗酒精性脂肪肝32例[J]．河南中医，1997，17(4)：225-226．
26．裴道灵．健脾疏肝法治疗脂肪肝42例小结[J]．湖南中医杂志，2000，16(3)：35-36．
27．谭剑霞，陶琼．清浊降脂汤治疗脂肪肝47例[J]．湖南中医杂志，2000，16(3)：35-36．
28．黄哲，田德禄．中医药防治酒精性肝病的研究进展[J]．北京中医药大学学报，2003(2)：72．
29．符朝岩，刁秀兰．降脂护肝冲剂治疗脂肪肝的临床研究[J]．辽宁中医杂志，2000(12)：551-552．
30．银醇云．辨证治疗脂肪肝58例临床观察[J]．湖南中医药导报2003，9(8)：20-21．
31．赵秀莉．中医辨治脂肪肝[J]．中国社区医师，2003，19(16)：13-14．
32吴益萍．辨证分型治疗脂肪肝87例[J]．实用中医药杂志，2000，16(7)：14．
33．谢绍武．脂肪肝病辨证分型用药探析[J]．中医药学刊，2003，19(5)：503．
34．裴道灵．周文卫主任治疗脂肪肝经验[J]．黑龙江中医药2000，(6)：39-40．
35．董汉良．脂肪肝的证治探析[J]．中国社区医师，2003，18(10)：35-36．
36．陈腾云，何敏．脂肪肝中医辨证论治体会[J]．中国误诊学杂志，2005，5(13)：2550-2551．
37．刘志诚，施小波，王沂争，等．针灸对单纯性肥胖病高密度脂蛋白胆固醇的影响[J]．针刺研究，1990，(3)：227．
38．王克勤．脂蛋白与动脉粥样硬化[M]．北京：人民卫生出版社，1995．348．
39．王玉堂，安华．针刺丰隆穴降血脂47例临床观察[J]．中国针灸，1990，(3)：21．
40．许玉民．针刺对缺血性中风血脂变化的观察．上海针灸杂志，1992，11(2)：13..
41．严洁，白净净，易受乡，等．针刺降血脂的疗效观察，中医杂志，1987，(8)：43．
42．李国鹏，任惠娟．针灸对女性更年期综合征高密度脂蛋白亚组分和其他脂质含量的影响[J]．南京中医学院学报，2002，18(11)：53-54．
43．戚丽宣，张仲徽，叶成鸪等．针刺治疗脑梗塞322例临床疗效及对血清高密度脂蛋白胆固醇、血液流变学、纤维蛋白元等指标观察，中国针灸，1988,10(3)：21．
44．陈瑞，梁凤霞，毛红蓉．针刺从脾论治高脂血症的临床研．中国中西医结合消化杂志，2003，11(3)：162．
45．焦新民，殷克敏，申卓彬，等．针刺降低血脂82例临床观察[J]．新中医，1985，(6)：32．
46．毛喜荣，王月冬，周逸平．针刺对冠心病患者血脂血糖的影响[J]．针灸临床杂志，1994，10(2)：26．
47．李忠仁，陆念祖，王肖曼，等．针刺治疗中风高脂血症临床观察[J]．中国针灸，1988，(4)：28．
48．常小荣，周国平，严洁，等．隔药饼灸对高脂血症患者血清HDL-C、LDL-C及其他脂质含量的影响．中国中医基础医学杂志，1999，5(2)：53．
49．蒋桂素．艾灸对血清三酸甘油酯及胆固醇的降脂作用观察[J]．上海针灸杂志，1987，(3)：11．
50．王凤玲，王晓红，王巧妹，等．灸神阙穴降脂抗衰老作用的研究[J]．中国针灸，1996，(9)：29．
51．高耀华，王竹行，陈新黔，等．降脂药灸治疗中老年高脂血症的临床研究．中国针灸，2000，20(2)：77
52．刘运珠．温针灸足三里对防治老年性疾病的临床观察[J]．中国针灸，1996，16(9)：7．
53．吴中朝，王玲玲，刘跃光，等．艾灸对老年人血液载脂蛋白研究[J]．中国针灸，1998，(5)：261．
54．陈晓萍．耳穴贴压法治疗高脂血症．上海中医药杂志，1991；(10)：27．
55．刘丕成．足三里穴位穿刺埋线对人体血清胆固醇的影响．新中医，1980；(5)：39
56．袁俏梅，史红辉．穴位埋线治疗高脂血症34例—附普拉固治疗30例对照[J]．浙江中医杂志，2002，37(9)：396．
57．唐胜修，唐萍．丰隆、足三里穴位注射治疗高脂血症的临床研究．广西医学，2000，22(6)：1402．
58．王华．丹参穴位注射治疗高脂血症40例临床分析[J]．中国针灸，1997，(8)：469-469．
59．张静．熊胆注射液穴位注射治疗高脂血症临床疗效观察[J]．针灸临床杂志，2001，17(3)：14-15．
60．刘晓辉．当归维生素B12混合穴位注射治疗高脂血症56例[J]时珍国医国药，2001，12(4)：360．
61．袁凌松，朱忠春，余明哲．针药结合对不同部位脑梗塞患者血清高、低密度脂蛋白的影响．上海中医药大学学报，2001，15(2)：28.
62．梁凤应．针灸对老年人高脂血症及高粘血症的影响．上海针灸杂志，1999，18(4)：10．
63．张向力，张丽萍，邹璐．针药并用治疗高脂血症50例临床观察．针灸临床杂志，2001，17(7)：2．
64．范冠杰，彭颖华．针药合用对非胰岛素依赖型糖尿病患者血脂影响的临床研究．中国针灸，1998，18(3)：139．
65．朱雅萍．电针治疗高脂血症60例[J]．吉林中医药，2001，(4)43-43．
66．韩舰华．不同时辰电针足三里对实验性高脂血症家兔的疗效观察．针刺研究，1998，(4)：278．
67．程井军，吴其恺，贺劲松，等．电针治疗非酒精性脂肪性肝炎的临床观察．湖北中医杂志，2005，27(8)：9-11．
68．广西南宁针灸研究所．针灸治疗心血管病高血脂51例临床疗效观察[J]．中国针灸，1982，(4)：10．
69．杨一明，靳瑞，张家维．针刺对高脂血症患者高密度脂蛋白亚组分和其他脂质含 量的影响[J]．针灸学报，1992，(1)：7．
70．刘志诚，孙凤岷，赵东红等．针刺对单纯性肥胖瘦素和胰岛素抵抗的影响研究．中医药学刊，2003，21(1)：40-42．
71．刘志诚，孙凤岷，朱苗花，等．针灸对非胰岛素依赖性糖尿病胰岛素抵抗的影响[J]．上海针灸杂志，2000，19(1)：5-7．
72．谌剑飞，马雅玲，丁萍，等．针刺对2型糖尿病患者免疫细胞因子、胰岛素敏感指数及血凝指标的影响[J]．中医杂志，2002，43(1)：30-32．
73．苗宇船，李瑞华．复方中药防治大鼠脂肪肝的实验研究[J]．山西中医学院学报，2003，4(2)：15-17．
74．何东仪，胡义扬．肝脂消方对ccl_4诱导大鼠肝脂肪变性时HDSase、ATPase的影响[J]．中国中西医结合消化杂志，2001，9(3)：133-135．
75．杨东娣，黄真炎．虎金丸对大鼠脂肪肝超微结构变化的影响[J]．中医药研究，2001，17(5)：43-44．
76．马晓燕，季雅玲．肝脂消煎剂对脂肪肝大鼠肝微粒体膜流动性及心肌黄酶、丙二醛的作用[J]．中国中西医结合消化杂志，2004，10(5)：284-286．
77．张卓，顾恪波．消脂护肝方对非酒精性脂肪肝大鼠脂质过氧化的影响[J]．中西医结合肝病杂志，2004，14(3)：155-157．
78夏瑾瑜，贾学平．肝脂康胶囊对非酒精性脂肪肝的防治作用[J]．中国中西医结合消化杂志，2004，12(1)：15-18．
79．官昭艳．双清片对大鼠实验性脂肪肝影响的实验研究[J]．中国中医药科技，2005，12(3)：156-157．
80．李石良，陈汉平，郑蕙田，等．针刺艾灸改善NIDDM大鼠脂代谢紊乱的作用机理[J]．针灸临床杂志，1995，11(2)：19．
81．杨丹红，许文波，江庆淇．穴位注射对高脂血症动物模型的降脂作用．针灸临床杂志，2000，16(1)：43．
82．王玉琴等．针刺对高胆固醇血症家兔影响的研究．中国针灸，1994；(2)：32．
83．程井军，吴其恺，贺劲松，等．电针对非酒精性脂肪性肝炎大鼠血清TNF-α及RI的影响．湖北中医学院学报，2005，7(3)：21．
84．桂金水，陈汉平，张时宜．艾灸抑制豚鼠肝脂肪变性的形态学观察[J]．解剖学杂志，1990，13(2)：110．
85．孙璇，李学武．天灸对大鼠脂肪肝治疗作用的实验研究[J]．北京中医药大学学报，2001，24(1)：48．
86．王凤珍，杨钦河，王强，等．中医药治疗脂肪肝临床研究进展．安徽中医学院学报，2006，25(1)：53．
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |